The Role of p16INK4a Expression in the Age-related Risk of Venous Thromboembolism by Cardenas, Jessica Caroline
 THE ROLE OF P16INK4A EXPRESSION IN THE AGE-RELATED RISK OF  
VENOUS THROMBOEMBOLISM 
Jessica Caroline Cardenas 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Pathology and Laboratory Medicine. 
Chapel Hill 
2012 
Approved by: 
Frank C. Church, PhD 
 
Nigel S. Key, MD 
 
Norman E. Sharpless, MD 
 
Herbert C. Whinna, MD, PhD 
 
Alisa S. Wolberg, PhD 
 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2012 
Jessica Caroline Cardenas 
ALL RIGHTS RESERVED 
 iii 
 
Abstract 
 
JESSICA CAROLINE CARDENAS: The Role of p16INK4a Expression in the Age-related 
Risk of Venous Thromboembolism 
(Under the direction of Dr. Frank C. Church) 
Venous thromboembolism (VTE) is a pathophysiologically complex disease involving 
dysregulation of pro and anticoagulant processes in the vasculature.  Aging is the strongest 
risk factor for VTE, although the mechanism is not well understood.  Senescence is a 
physiologic process limiting cellular proliferation, caused by age-dependent expression of the 
cell cycle inhibitor p16INK4a.  p16INK4a expression and senescence could promote vascular 
dysfunction and predispose elderly individuals to VTE.  This dissertation is focused on 
researching the contribution of p16INK4a expression and aging to venous thrombosis.  
Murine in vivo vascular injury models are commonly used to study venous and arterial 
thrombosis.  We found that p16INK4a overexpression in mice was associated with augmented 
venous thrombosis and increased thrombin generation.  Bone marrow transplantation 
analysis demonstrated that this phenotype was dependent on p16INK4a expression in 
hematopoietic cells.  Furthermore, p16INK4a transgenic mice display significant elevation 
monocyte and macrophage marker, F4/80 staining following IVC ligation.  Depletion of 
monocytes and macrophages, abolished the difference in thrombus mass between p16INK4a 
overexpressing and wild-type mice.  This suggests that p16INK4a expression in hematopoeitic 
cells, and specifically monocytes and macrophages, contribute to venous thrombosis.  
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Senescence in vascular endothelial cells is associated with phenotypic changes that could 
promote vascular dysfunction.  We observed that senescence induced by serial passaging in 
vitro caused more rapid rates of clot formation, increased thrombin generation, and formation 
of denser fibrin networks on the endothelial cell surface.  Furthermore, senescent endothelial 
cells generate less activated protein C due to downregulation of thrombomodulin expression.   
These results suggest that endothelial cell senescence promotes a procoagulant phenotype. 
Age-related changes in venous thrombus formation and resolution have not been well 
defined.  Aged mice display a prothrombotic phenotype in a FeCl3 injury to the saphenous 
vein, however there was no difference compared to young mice in thrombus mass after IVC-
ligation.  This suggests the susceptibility of aged mice to venous thrombosis is coagulation 
stimulus dependent.  Additionally, aging in mice is associated with changes in blood 
composition and plasma coagulability that differ from changes observed in human aging, 
suggesting mice are a challenging model to study hemostasis during aging. 
Collectively these studies suggest that p16INK4a expression and cellular senescence 
contribute to venous thrombosis. 
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Chapter 1 
Introduction 
Venous Thromboembolism and the Increased Risk with Age 
 
1.1 Introduction. 
Deep vein thrombosis (DVT) is characterized by the formation of occlusive or semi-
occlusive thrombi typically in the deep veins of the limbs.  The most serious and potentially 
fatal complication of a DVT is pulmonary embolism (PE), in which part of the thrombus 
breaks off (embolizes), traveling through the circulation before becoming lodged in the 
pulmonary artery.  DVT and PE are collectively referred to as venous thromboembolism 
(VTE).  The incidence of VTE is approximately 1 in 1000, with between 350,000 and 
600,000 individuals affected by this disease each year in the United States1,2.  There are 
many risk factors for VTE, both genetic and acquired/environmental.  The strongest acquired 
risk factor is age3.  Interestingly, the rate of VTE increase relatively slowly until the age of 
50, after which there is a dramatic increase with an incidence of 1 in 100 over the age of 
752,4.  In the U.S., over 250,000 VTE patients are hospitalized each year, contributing to the 
significant healthcare economic burden associated with cardiovascular disease.  The national 
annual cost of VTE is estimated at $1.5 billion5.  With the incidence of VTE predicted to 
increase dramatically in the future with the aging population, we can expect the economic 
burden to continue to rise. 
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Virchow’s triad can be used to explain the etiology of thrombosis: changes in blood 
vessel (arterial and venous thrombosis) due to endothelial injury, secondary to diseases like 
atherosclerosis, trauma or chronic inflammation; changes in blood constituents (venous 
thrombosis) due to primary hypercoagulability (e.g., antithrombin deficiency or Factor 
VLeiden) or acquired hypercoagulability (e.g., age, obesity, pregnancy, smoking, 
trauma/surgery, or cancer); and changes in blood flow (venous thrombosis) such as caused by 
stasis or vessel turbulence especially behind venous valve pockets.  One or more aspects of 
Virchow’s triad may change with advanced aging, although the relationship between VTE 
and age is poorly understood.  Several publications have reviewed the effect of aging on 
hemostasis/thrombosis6-8.  Here we review recent findings concerning age-related changes in 
the hemostasis system that may predispose elderly individuals to VTE. 
 
1.2 Review of hemostasis. 
Under normal, physiologic conditions, luminal flowing blood comes into contact only 
with circulating blood cells and the naturally anticoagulant vascular endothelium.  Upon 
perturbation or injury to the vessel wall, sub-endothelial tissue factor (TF) expressed by cells 
such as fibroblasts and smooth muscle cells is exposed to the flowing blood, becoming 
available for complex formation with circulating activated factor VII (Figure 1.1).  This 
TF/FVIIa complex initiates the coagulation pathway by activation of both factor X (FX) to 
activated factor X (FXa) and factor IX (FIX) to activated factor IX (FIXa) .  FXa bound to its 
cofactor activated factor V (FVa) then cleaves prothrombin to its active form, thrombin.  This 
is the initiation phase of coagulation.  The relatively small amount of thrombin generated 
during the initiation phase can then activate factor XI, factor VIII and factor V and activate 
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platelets that will adhere to the site of injury by cleavage of the protease-activated receptors 
on the platelet surface.  In addition, thrombin stimulates microparticle release from platelets 
and circulating monocytes.  Rich in TF and phosphatidyl serine (PS), microparticules (MP) 
support FXa generation an are thus critical in promoting thrombin generation and further 
platelet activation.  Even greater activation of FIX by FXIa and FX occurs on the PS-rich 
platelet surface by the FIXa and FVIIIa complex, also known as the TENase complex (Figure 
1.1).  Also on the platelet surface, FXa binds with its cofactor, FVa (all together referred to 
as the prothrombinase complex) generating a large volume burst of thrombin (Figure 1.1).  
This is termed the propagation phase of coagulation and this process cycles to produce more 
and more thrombin.  The generation of thrombin is a key event in the coagulation cascade, as 
thrombin is the protease that cleaves circulating fibrinogen to fibrin.  The more thrombin that 
is generated, the more fibrinogen can be cleaved to fibrin to form a fibrin clot, a structure 
which is stabilized and made insoluble through fibrin cross-linking by activated factor XIII 
(FXIIIa), a transglutaminase.   
Therefore, blood clots are composed of activated plasma factors, trapped leukocytes and 
red blood cells, activated platelets, MPs and fibrin.  Fibrin-rich venous clots and platelet-rich 
arterial clots differ in composition, suggesting that while thrombin is generated through the 
same mechanism, differences in shear flow rate favor fibrin deposition over platelet adhesion 
in the venous circulation, whereas shear rates in the arterial circulation favor platelet 
adhesion over fibrin deposition. 
As aberrant or sustained clotting can be pathological, several very important 
anticoagulant and fibrinolytic pathways also regulate blood coagulation and clot dissolution.  
The protein C pathway is an essential anticoagulant regulatory pathway designed to inhibit 
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the propagation of thrombin (Figure 1.1).  As part of their anti-thrombotic surface, vascular 
endothelial cells produce thrombomodulin (TM), a trans-membrane glycoprotein that binds 
to thrombin and in the presence of endothelial protein C receptor (EPCR) which binds 
zymogen Protein C.  The TM/thrombin complex cleaves protein C bound to EPCR to 
activated protein C (APC) (Figure 1.1).  APC can then interact with its cofactor, protein S, to 
inactivate FVa and FIIIa; thus down-regulating the further generation of thrombin.  In 
addition to TM and EPCR, vascular endothelial cells also produce heparan sulfate and 
dermatan sulfate, molecules that increase the efficiency of thrombin inhibition by 
antithrombin and other serine protease inhibitors (SERPINs).  Endothelial cells also produce 
key platelet inhibitors, including prostacyclin and nitric oxide, limiting the availability of 
lipids for coagulation factor complex formation. 
In addition to pathways in place to control clot formation and prevent the generation of 
occlusive thrombi, fibrinolysis or clot dissolution must also be regulated.  The fibrinolysis 
pathway is the pathway that dictates whether clots are sustained or dissolved (Figure 1.1).  
Endothelial cells and trapped leukocytes release both tissue and urokinase plasminogen 
activator (tPA and uPA, respectively), proteases which activate plasminogen to plasmin.  
Plasmin is a serine protease that cleaves cross-linked fibrin to produce fibrin degradation 
products, which are easily swept away and degraded in flowing blood.  Inhibitors tightly 
regulate fibrinolysis.  Plasmin is inhibited by α2-antiplasmin.  The primary inhibitor of both 
tPA and uPA is plasminogen activator inhibitor (PAI-1).  PAI-1 binds to the active site on 
tPA and uPA, blocking their ability to interact with plasminogen, therefore inhibiting 
fibrinolysis. 
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Blood coagulation is a complex cascade of proteases and protease inhibitors present in 
the circulation and synthesized by various cell types.  Given this, alterations to plasma 
proteins and platelet and endothelial function have significant, detrimental effects on 
coagulation. 
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Figure 1.1.  Coagulation Regulation:  The coagulation pathway is composed of a cascade 
of proteases that activate platelets and ultimately generates thrombin to cleave fibrinogen to 
fibrin.  This cascade is regulated by a number of protease inhibitors that limit the generation 
of thrombin, as well as the endothelial-derived protein C pathway which inactivates FVa and 
FVIIIa.  The sustained presence of a thrombus is regulated by the fibrinolysis pathway, 
which controls fibrin degradation. 
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1.3 Age-related increases in coagulation factors. 
A number of large-scale studies have measured the changes in coagulation factors with 
respect to age.  One of the coagulation proteins most commonly reported to increase with age 
is fibrinogen9, with levels ranging from 250 mg/dL in young, 20 year old subjects to 300 
mg/dL in subjects over 65 years of age10,11.  As the precursor to fibrin, fibrinogen availability 
is a key determinant in the formation of stable thrombi.  Elevated fibrinogen is a strong risk 
factor for cardiovascular disease, and while its role in arterial disease is widely accepted, the 
contribution of elevated fibrinogen levels to venous thrombosis has been considered 
controversial.  The first study attempting to correlate elevated fibrinogen with the risk of 
VTE included some of earliest patients in the Leiden thrombophilia study12.  With limited 
numbers, elevated fibrinogen was considered weakly predictive of VTE, however, when later 
expanded to include more patients, a positive correlation was found among patients with 
fibrinogen levels in the 95th percentile having a 2.8-fold increased risk of VTE13.  More 
recently, a study using mouse models showed that elevated fibrinogen plays a causative role 
in enhancing thrombosis in both arterial and venous models14.  Therefore, elevated 
circulating fibrinogen in elderly individuals may predispose them to coagulation 
abnormalities in the arterial and venous circulation. 
FVIII levels are also known to increase with age15-17.  With its cofactor FIXa, FVIII is a 
potent activator of FX that in turn, cleaves prothrombin to thrombin.  Thus, elevated FVIII 
has long been believed to be a risk factor for VTE, and as of recently, also for arterial 
thrombosis18.  A prospective cohort study showed a 11-fold increase in the risk of VTE for 
individuals with FVIII levels above the 90th percentile19.   
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FVIII circulates bound to von Willebrand Factor (vWF) and as such, age-related 
increases in vWF have also been observed9.  vWF is an endothelial-derived protein that 
functions as a strong platelet tethering agent.  It was thought that vWF only contributed to the 
risk of VTE through its association with, or effect on levels of FVIII20.  However the 2002 
LITE study showed that FVIII and vWF are in fact independent risk factors for VTE21.  
Mouse models have recently shown that both vWF and FVIII are independently critical for 
venous thrombus formation.  vWF knock-out mice show impaired venous thrombus growth 
and platelet adhesion following FeCl3 injury, a defect that was not fully corrected upon 
infusion of recombinant FVIII although FVIII infusion did increase thrombus stability22.  
These data support findings from the LITE study that even uncomplexed vWF and FVIII can 
both contribute to venous thrombosis. 
FVII is a circulating zymogen that, when in complex with its cofactor TF, is a potent 
initiator of coagulation.  Levels of FVII are reported to increase over 15 units/dL between the 
ages of 20 and 50 years9,23.  Considering that increases in circulating FVII should be 
relatively harmless given that TF is typically not found circulating or even available on the 
endothelial surface in the absence of an injury or disease state, its contribution to VTE 
remains controversial10,20,21,24.  Recent data in mouse models show that stress is a potent 
inducer of TF expression in mouse models of aging and obesity25.  This suggests that during 
normal, physiologic aging and chronic pathologic conditions where individuals are more 
susceptible to stress, elevated TF may interact with FVII, thus making elevated FVII an 
important risk factor for VTE.  
The zymogen FIX, a member of the TENase complex with cofactor FVIII, also 
undergoes an age-depended increase26.  Given its importance in the activation of FX to 
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subsequently enable the generation of thrombin, elevated FIX levels are thought to be a risk 
factor for VTE.  Data from the LETS study concluded that those with FIX levels above the 
90th percentile had an odds ratio of 2.3 and were at elevated risk of VTE27. 
Other coagulation proteins known to increase with age include high molecular weight 
kininogen, prekallikrein and thrombin activatable fibrinolysis inhibitor (TAFI); however, 
these increases are not thought to significantly elevate the risk of VTE. 
It is important to note that while procoagulant markers do increase with age, this may not 
always correlate with the risk cardiovascular disease.  Multiple studies have reported 
increases in coagulation factors in healthy, elderly individuals who do not suffer from arterial 
or venous diseases10,28,29.  These studies suggest that elevated procoagulant proteins may be a 
better marker of aging than of cardiovascular disease risk. 
  
1.4 Age-related changes in anticoagulant factors. 
Very little data exists in the literature to suggest that levels of natural anticoagulants 
diminish with age as a means of explaining the increased risk of VTE.  In fact, particularly in 
women, levels of certain anticoagulants such as protein C, protein S and antithrombin (AT) 
reportedly increase with age30, most commonly during menopause31.  Levels of these same 
anticoagulants remained unchanged in aging men.  Similarly, age-related increases in tissue 
factor pathway inhibitor (TFPI), the primary inhibitor of TF initiated coagulation, have been 
observed in both men and women10,30,32. 
Conversely, there is a growing body of evidence in mouse models to suggest that aging is 
associated with a reduction in endothelial-bound levels of anticoagulant TM33,34.  A decrease 
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in available TM to bind thrombin would result in diminished APC generation.  However, this 
data has yet to be confirmed in humans. 
Given the above data, it appears that while changes in levels of natural anticoagulants 
with age alone do not contribute to the risk of VTE, the combination of increased 
procoagulants in the absence of concomitant increases in anticoagulants may predispose 
elderly individuals to venous and arterial disease. 
 
1.5 Age-related changes in plasminogen activation. 
The plasminogen activation system is the primary pathway regulating fibrinolysis.  Well-
documented age-related alterations to this pathway that result in impaired thrombus 
resolution have been reported.  Plasminogen activator inhibitor (PAI-1) is an important 
inhibitor of fibrinolysis and elevated levels of this protein have been reported in aging and a 
variety of other disease states9,31.  Data from the Framingham cohort found that PAI-1 
antigen levels in plasma went from 19.4 ng/mL in men under 40 years old to 24.6 ng/mL in 
those 70 years and above, with similar increases found in women9.  PAI-1 itself is 
cardioprotective and is thought to maintain vascular integrity, as evidenced by data in PAI-1 
deficient mice which show increased cardiac fibrosis likely as a result of increased 
inflammation and endothelial leakage35,36.  However, in humans, elevated PAI-1 levels are 
positively correlated with the risk of thrombotic events37,38.  Plasma levels of tissue 
plasminogen activator (tPA) are also elevated with age9,31,39.  The mechanism behind 
concurrent increases in both tPA and PAI-1 in elderly individuals are not known.  
Additionally, although levels of circulating plasminogen were found to decrease only slightly 
in women with age40, levels of plasmin-α2-antiplasmin (PAP) complex increase41 with age.  
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The SERPIN α2-antiplasmin is an important inhibitor that inactivates plasmin, thus is an 
inhibitor of fibrinolysis.  Collectively, the combined increases in fibrinolysis inhibitors PAI-1 
and α2-antiplasmin even with concomitant increases in tPA could predispose elderly 
individuals to impaired thrombus resolution 
 
1.6 Effect of age on platelet function. 
Platelets are key mediators of primary hemostasis in that they are crucial in stopping 
early bleeding and provide a lipid-rich surface for the generation of coagulation proteases.  
Patients with low platelet counts (thrombocytopenia) as a result of infection, malnutrition, 
cancer, or genetics suffer symptoms ranging from minor fatigue to severe bleeding.  
Interestingly, aging in humans is associated with a decrease in circulating platelet counts42-44, 
with an estimated decrease of 6 x 109/L for every 10 years of age43.  It remains unclear 
whether this decrease in platelet counts is due to reduced hematopoiesis, decreased 
production from megakaryocytes or increased clearance by the speen. 
Despite the reduction in platelet number, aging is associated with differences in platelet 
function.  While there is very little current data in this area, historical data has given insight 
into how platelet biology changes with age.  Increased platelet aggregation in response to 
ADP, collagen, and adrenaline has been observed in platelets from aged individuals, in 
addition to increased ATP release upon collagen stimulation45,46.  Platelets from older 
individuals also display reduced ADP thresholds for aggregation compared to those from the 
young, further suggesting they are more sensitive to certain agonists47.  It is thought that this 
hyperreactivity is due to increased platelet expression of receptors for these agonists48,49.  
Also, platelets from the elderly produce more thromboxane A2 which is involved in platelet 
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activation and formation of platelet aggregates50.  This could have clinical implications for 
treating elderly patients with antiplatelet agents such as clopidogrel, an inhibitor of the 
platelet P2Y12 receptor for ADP.  A recent study found that the linear age-related increase in 
ADP-induced platelet aggregation was associated with reduced sensitivity to initial 
clopidogrel51. 
Aside from biological changes that occur with age in platelets themselves, age-associated 
changes in endothelial function could also promote platelet hyperreactivity.  These include 
increased endothelial production of vWF, which could result in enhanced platelet tethering to 
endothelial cell surfaces52.  Also, decreased production of endothelial nitric oxide synthase 
(eNOS) results in dowregulation of nitric oxide (NO) generation.  NO is a potent inhibitor of 
platelet activation53,54.  Decreased levels of this important inhibitor could result in 
dysregulation of platelet activation and the inappropriate release of procoagulant material 
from platelet granules.   
  
1.7 Effect of aging on the vascular endothelium. 
Understanding the interplay between the components of Virchow’s triad is necessary to 
effectively diagnose and treat bleeding and thrombotic disorders.  Increasing awareness of 
the complexities of these presentations, along with increasingly sophisticated technologies to 
analyze soluble, cellular, and physical dysfunctions in concert will shed new light on these 
pathologies and identify novel therapeutic targets.  With such targets, we can achieve the The 
vascular endothelium plays an important role in regulating blood coagulation through its 
anticoagulant properties.  These include production of the thrombin inhibitors TM, EPCR, 
heparan and dermatan sulfate, creating a physical barrier to block exposure of sub-
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endothelial tissue factor from flowing blood, release of tissue factor pathway inhibitor (TFPI) 
to inhibit TF activity, and initiating fibrinolysis through release of plasminogen activators.  
Endothelial dysfunction is a widely accepted consequence of aging and can turn the 
naturally anticoagulant endothelial cell surface into one that is more procoagulant.  Many 
age-related changes have been reported to occur in the vascular endothelium, one of which is 
increased vascular permeability.  The loss of cell-cell junctions with age results in vascular 
leakage, exposure of subendotheial proteins (i.e. TF), and leukocyte adhesion55.  Aged 
endothelial cells also produce more anti-fibrinolytic PAI-156 and, in animal models, less 
anticoagulant TM upon treatment with endotoxin34.  There is also increased production and 
secretion of pro-inflammatory cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) from 
aged endothelium, promoting recruitment and binding of leukocytes to the cell surface57.  
Aging is also associated with a loss of eNOS production, resulting is reduced availability of 
NO to regulate vessel dilation and platelet activation53,54. 
 
1.8 Vascular inflammation and age. 
The relationship between aging and chronic inflammation is well recognized, yet poorly 
understood.  Similarly, the relationship between inflammation and aging is not fully 
apparent, however it is widely studied.  Many of the procoagulant and antifibrinolytic 
proteins that increase with age are, in fact, acute phase reactants (i.e. fibrinogen, FVIII, and 
PAI-1) that are sensitive to and regulated by inflammatory cytokines.  These cytokines also 
have a profound effect on vascular endothelial cells.  In cell culture, stimulation with TNF-α 
results in the increased production of TF and PAI-1 and decreased production of TM by 
endothelial cells58.  In vitro, endothelial cells will only contribute to thrombin generation on 
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their cell surface after such stimulation59.  Circulating plasma levels of TNF-α reportedly 
increase with age60,61, and, given its importance in vitro, this inflammatory cytokine could 
regulate thrombin generation in vivo by increasing endothelial procoagulant and decreasing 
protein production in endothelial cells. 
IL-6 is another inflammatory cytokine that increases in an age-dependent manner62.  IL-6 
is capable of both pro and anti-inflammatory functions, limiting its own production and 
inhibiting other cytokines.  IL-6 is also involved in acute phase responses to infection and 
trauma; it can stimulate the production of neutrophils from the bone marrow and promote the 
synthesis of C-reactive protein (CRP) by hepatocytes.  CRP itself is proinflammatory and is 
used as a marker of inflammation.  Increased CRP levels are predictive of cardiovascular 
disease and have recently been shown in a transgenic rabbit model to enhance thrombus 
formation after neointimal injury63.  Cytokine expression may also promote TF release by 
circulating monocytes and recruit leukocytes to endothelial cells surfaces.  Monocyte 
chemotactic protein-1 (MCP-1) is a chemokine produced by endothelial cells, monocytes and 
macrophages.  The recruitment of leukocytes to dysfunctional endothelium may lead to 
propagation of cytokine release by these leukocytes and promote coagulation, as expression 
of MCP-1 and IL-6 are both risk factors for recurrent VTE64.  Giving credence to the 
importance of inflammation in promoting VTE, data from the JUPITER study suggests 
patients on statins have reduced inflammation and a lower risk of VTE65. 
 
1.9  Immobility with age. 
Venous thrombi are most likely to develop within a valve pocket where blood can form 
eddies or circular flow patterns, suggesting that irregular blood flow is a risk factor for 
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thrombosis.  Immobility reduces the rate of blood flow leading to the stagnation of blood, 
referred to as stasis.  Stasis not only causes the pooling of blood and procoagulant materials 
in large veins, but also reduces the ability of the blood to circulate through the 
microvasculature where contact with anticoagulants is highest66.  Elderly individuals are at 
increased risk of immobility, and therefore stasis, due to an age-related reduction in activity 
and increased susceptibility to frailty and infection4. 
 
1.10  Conclusions. 
The increased risk of VTE with age can be due to a variety of alterations in the 
hemostatic system.  VTE itself is a multifaceted disease, triggered by a complex interplay of 
risk factors.  We can expect the healthcare burden associated with VTE to increase 
exponentially as the population ages.  More research in this field is critical for further 
defining and understanding how physiologic aging affect coagulation in the venous 
circulation. 
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Chapter 2 
Introduction 
The Role of p16INK4a Expression in Aging and Cardiovascular Disease 
 
2.1  Introduction. 
The gene products encoded by the INK4b-ARF-INK4a locus play a critical role in 
regulating cell cycle progression and are thus important for inhibiting malignant 
transformation1,2.  Of the two cyclin-dependent kinase inhibitors encoded on this locus, 
expression of p16INK4a increases in an age-dependent manner.  A known biomarker of human 
and murine aging3,4, the contribution of p16INK4a to age-related diseases is the focus of many 
recent reports.  Genome-wide association studies suggest p16INK4a plays a protect role in 
many cardiovascular diseases affecting the arteries, likely through its anti-proliferative 
function5,6.  Conversely, p16INK4a expression may contribute to diseases of the venous 
circulation by promoting endothelial dysfunction upon induction of senescence in the 
vasculature7-9.  This review focuses on the structure, function, and regulation of the INK4b-
ARF-INK4a locus and recent publications that offer insight into how p16INK4a may promote 
or protect from age-related pathologies. 
 
2.2  INK4b-ARF-INK4a structure and function. 
 The INK4b-ARF-INK4a locus, located on chromosome 9p21, is approximately 35kb in 
length and encodes for three proteins critical in regulating cellular proliferation.  Two of 
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these proteins are the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a while the 
third, p14ARF (ARF), is involved in stabilizing p531,2.  In terms of genomic structure, p15INK4b 
lies upstream of p16INK4a and ARF, and utilizes its own coding region.  Downstream of 
p15INK4b lies the shared coding region for p16INK4a and ARF.  This region contains two 
alternatively spliced first exons: exon 1α and exon 1β, each containing their own promoter.  
In the case of ARF, exon 1α is spliced to exons 2 and 3 to produce the ARF transcript.  In the 
case of p16INK4a, exon 1β is spliced to exons 2 and 3, producing the p16INK4a transcript.  
Together, these genes are referred to as CDKN2A (Figure 2.1)1,2.   Interestingly, the INK4b-
ARF-INK4a locus also encodes a non-coding RNA called antisense non-coding RNA in the 
INK4 locus (ANRIL) (Figure 2.1).  Although its function is not yet fully understood, it likely 
plays an important role in regulating gene expression from this locus1,2,10. 
Functionally, both p15INK4b and p16INK4a are cyclin-dependent kinase (CDK) inhibitors.  
They bind to CDK4 and CDK6 causing an allosteric conformational change, disrupting the 
ability of these CDKs to bind to D-type cyclins.  In cycling cells, CDK/cyclin complexes 
regulate the cell cycle through interaction with the retinoblastoma protein (Rb)1,2,11.  
Unmodified, Rb is bound to the transcription factor, E2F, which remains inactive while 
bound to Rb.  Upon phosphorylation of Rb by the CDK/cyclin complex during cell cycle 
progression, Rb dissociates from E2F which can now bind to DNA and initiate transcription 
of genes involved in promoting cell cycle progression (Figure 2.2).  Therefore, p15INK4b and 
p16INK4a inhibit cell cycle progression by blocking the phosphorylation of Rb by CDK/cyclin 
complexes, causing cell cycle arrest in G1 phase1,2,11. 
The ARF gene product can also regulate cell cycle progression or induce apoptosis 
through its effects on p53.  ARF interacts with MDM2, an inhibitor of p53 transcriptional 
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activation and therefore negative regulator of p53 activity.  ARF binds to MDM2 and keeps it 
sequestered in the nucleolus, making MDM2 unable to inhibit p53-mediated transcription.  
This, in turn leads to activation of p53 and either apoptosis or cell cycle arrest through 
upregulation of p21, a CDK4 and CDK2 inhibitors1,2,12-14. 
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Figure 2.1.  Genomic structure of the INK4b-ARF-INK4a gene locus.  Exons are color 
coded to represent the gene product they are spliced into.  Arrows represent promoters and 
direction of transcription.  ANRIL is encoded on the INK4a-ARF locus although the exact 
position is not known.  Schematic is not drawn to scale and positions are approximate. 
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Figure 2.2.  Mechanism by which p16INK4a regulates cell cycle progression through 
hypophosphorylation of Rb.  p16INK4a binds to CDK4 and 6 to disable interaction of D-type 
cyclins.  This maintains Rb in a hypophosphorylated state with E2F repressionally bound and 
thus inhibiting cell cycle progression and arrest in G0/G1 phase. 
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2.3 INK4b-ARF-INK4a regulation. 
The INK4b-ARF-INK4a locus encodes proteins which perform important tumor 
suppressor functions; most notably p16INK4a.  Loss of p16INK4a, in the absence of inactivation 
of p15INK4b or ARF, is observed in several human cancers15-18.  p16INK4a is activated in 
response to oncogenic signaling (i.e. RAS or RAF) or aberrant cellular proliferation and 
functionally inhibits tumor progression through negative regulation of the cell cycle1,19,20.  
p16INK4a is also activated during normal physiologic aging.  This is likely in response to the 
accumulation of low-level oncogenic signals and cellular stresses over time and evolved as a 
mechanism to prevent, or as a pre-emptive strike against malignant transformation21,22. 
Conversely, several negative regulators repress p16INK4a expression.  Among these is the 
DNA-binding protein ID-1.  ID-1 binds to and inhibits Ets-2, a transcription factor that 
activates the p16INK4a promoter, thus downregulating p16INK4a transcription23.  Additionally, 
p16INK4a and other parts of the INK4b-ARF-INK4a locus are repressed through negative 
regulation by Polycomb group (PcG) proteins.  Members of the PcG work cooperatively to 
form Polycomb repressive complex (PRC) 1 and 2, which functions by ubiquitinylation of 
histone H2A and methylation of histone H3 followed by transcriptional shut down of the 
epigenetically tagged chromatin.  A critical member of the PRC1 complex is Bmi-1, the only 
known PcG protein involved in repressing all three products of the INK4b-ARF-INK4b locus.  
Bmi-1 is involved in stabilizing the PRC1 complex24,25.  Although the mechanism is not 
completely understood, knocking down Bmi-1 in cell culture results in premature senescence 
and increased proteins levels of p15INK4b, p16INK4a and ARF26.  It is also thought that ANRIL, 
the non-coding RNA present on the CDKN2A locus, is also a negative regulator of p16INK4a 
expression.  ANRIL recruits PRCs to the coding region on this locus, thus inducing 
  28 
transcription repression of p16INK4a 25.  Thus a reduction in ANRIL expression is associated 
with increased p16INK4a expression27.  
  
2.4  Role of INK4b-ARF-INK4a in cellular senescence. 
 Cellular senescence is an irreversible growth arrest or terminal differentiation induced by 
a variety of stimuli.  There are two broad categories of cellular senescence: replicative and 
stress-induced senescence28.  Replicative senescence results from telomere attrition.  
Telomeres are nucleotide repeat ‘caps’ present at the chromosome ends and protect the last 
gene on the chromosome arm from deteriorating upon multiple divisions.  Inevitably, 
chromosomes shorten after each mitotic event due to the inability to copy the farthest ends of 
the DNA strand, called the “end-replication problem”.  A cell can only divide as many times 
as the telomeres will still be present to protect the coding regions.  This number is called the 
Hayflick Limit, or the number of times a cell can divide before sensing telomore attrition, 
triggering a DNA damage response and undergoing senescence in response to p53 
signaling28-31,7.  Interestingly, p16INK4a accumulates in fibroblasts with shortening telomeres, 
suggesting it may also play a role in promoting replicative senescence32.   
Alternatively, a cell can undergo senescence prior to reaching this limit and independent 
of telomere length in response to oncogenic or other environmental stresses.  This is called 
stress-induced senescence and is mediated by CDK inhibitors to promote cell cycle 
arrest28,31.  While each product of the INK4b-ARF-INK4a locus causes an irreversible cell 
cycle arrest, the most important effector of senescence in human cells is p16INK4a.  Studies 
have shown that activation of the Ras/Raf/Mek oncogenic pathway leads to constitutive 
activation of the Ets1/2 transcription factor promoting p16INK4a expression and subsequent 
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down-regulation of the Ets1/2 inhibitor, Id-130.   In addition to oncogene expression, stress-
induced senescence can be induced by reactive oxygen species, ionizing radiation, 
inflammation and a variety of other environmental pressures that could promote malignant 
transformation7.  Although the mechanisms driving stress-induced senescence are not 
entirely understood, induction of p16INK4a and hypophosphorylation of Rb are commonly 
observed upon treatment of fibroblasts and endothelial cells with these environmental 
stressors33. 
 
2.5  Role of p16INK4a in aging. 
There are 4 members of the INK4 class of CDK inhibitors.  Two of them, p18INK4c and 
p19INK4d, are highly expressed during development.  However, both p15INK4b and p16INK4a are 
undetectable during early life, suggesting they likely have no role in fetal development and 
rather function solely as tumor suppressors in adult tissues2,34.  As previously mentioned, 
p16INK4a expression increases during normal, physiologic aging in many different tissues.  In 
fact, p16INK4a has recently been proposed as a biomarker of physiologic, as opposed to 
chronologic, aging3.  How p16INK4a is regulated during aging, what signals promote age-
dependent expression and whether p16INK4a plays a causative role in aging or is just a marker 
of aging have not been fully elucidated. 
Our body relies on self-renewing cell compartments to replace damaged or healing tissue 
throughout a lifetime of “wear and tear”.  Stem cells exist normally in a quiescent state, but 
can be prompted to proliferate in response to the need to repopulate damaged tissue35,36.  
While most mature organs utilize non-self renewing strategies to replace damaged or dead 
cells, self-renewing stem cells exists in certain “high-turnover” organ compartments like the 
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bone marrow or intestines to provide undifferentiated, multipotent daughter cells with the 
same renewing potential as the parent cell36.  The clinical observation that donor age is an 
important determinant of successful long-term transplantation of certain organs such as bone 
marrow would suggest that self-renewing stem cells do age, and become functionally limited 
as they age36,37.  It was recently shown that p16INK4a expression increases in an age-dependent 
manner in peripheral blood leukocytes, a cell type that originates in the hematopoietic 
compartment4.  Additionally, Krishnamurthy et al demonstrated that aged, p16INK4a deficient 
mice display enhanced islet cell proliferation following streptozotocin treatment compared to 
age-matched wild-type controls.  Conversely, p16INK4a transgenic mice display reduced islet 
cell proliferation following the same cellular ablation, suggesting that p16INK4a expression in 
certain cell compartments contributes to the age-related decline in proliferation and tissue 
repair38.  These data suggest that p16INK4a is not only a biomarker of aging, but also 
contributes to organismal aging by limiting the capacity for cellular self-renewal. 
Expression of p16INK4a as a biomarker of aging is not only true in humans, but rodents as 
well, as established by Krishnamurthy et al3 and also tested in our lab (Figure 2.3).  In mice, 
the CDKN2A locus is present on chromosome 4.  It shares a high level of sequence homology 
with humans and although the ARF gene product is slightly smaller than in humans (thus 
called p14ARF rather than p19ARF), the p16INK4a proteins are orthologous between mice and 
humans39.  Therefore, mice are a useful tool for studying p16INK4a expression during aging. 
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Figure 2.3: Expression of p16INK4a in mouse kidneys with age.  Expression of p16INK4a in 
the kidneys of mice aged 2-24 months was measured by immunhistochemistry.  
Quantification was performed in Adobe Photoshop to count the number of positively stained 
pixels. 
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2.6  Role of Role of p16INK4a in cardiovascular disease.   
While there is no doubt that p16INK4a plays an absolutely pivotal role in preventing 
tumorigenesis, the role of p16INK4a in age-related diseases is less well understood.  A series of 
recent studies have identified several single nucleotide polymorphisms (SNPs) clustered 
around the INK4b-ARF-INK4a locus that are associated with Alzheimer’s disease, type 2 
diabetes, frailty, and coronary artery disease1,40-44. 
Age is one of the greatest risk factors for cardiovascular disease.  How the CDKN2A 
locus may contribute to cardiovascular disease has recently been widely explored.  Given its 
physiologic function as a cell cycle inhibitor, a role for p16INK4a expression in protecting 
against cardiovascular diseases associated with aberrant cellular proliferation, such as 
atherosclerosis, would seem intuitive.  However, studies looking at the effect of p16INK4a on 
atherosclerosis have not had totally uniform findings. 
The chromosome 9p21 locus was first identified in a large genome-wide association 
study (GWAS) looking for genetic variants associated with coronary artery disease (CAD)45.  
A common risk allele was discovered with several SNPs mapping to a narrow DNA sequence 
on this locus.  Positioned only a short distance away are the CDKN2B and CDKN2A loci, the 
closest coding regions to the CAD risk segment45,5. Several groups have independently 
confirmed this finding and have also mapped high-risk regions on this chromosome in 
GWAS analysis of other types of cardiovascular disease such as stroke, aneurysm, carotid 
artery disease, and heart failure5.  A recent publication from Liu et al reports that the 
individuals with SNP genotypes associated with CAD risk actually display a significant 
reduction in expression of p16INK4a 6.  Also, SNPs resulting in alterations in expression of 
ANRIL, a negative regulator of p16INK4a expression, also confer increased risk of CAD46.  
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Collectively, human studies overwhelmingly suggest that p16INK4a plays a role in protecting 
individuals from arterial disease.   
These findings prompted a number of genetic mouse model studies to look at how genes 
encoded by these loci affect cardiovascular disease.  A recent study by Gonzalez-Navarro et 
al demonstrated that the p19ARF-/- mouse crossed to the ApoE-/- displayed increased 
atherosclerosis47.  Similarly, an independent report by Kuo et al showed that bone marrow 
transplantation from mice with heterozygous deficiency for both p19ARF and p16INK4a into 
Ldlr-/- mice results in increased atherosclerosis48.  
Conversely, Visel et al deleted a specific non-coding region on the CDKN2A locus 
thought to be orthologous to the human ANRIL non-coding RNA, which functionally 
represses p16INK4a expression.  While deletion of this region resulted in significant down-
regulation of both CDKN2B and CDKN2A with subsequent increases in cellular proliferation, 
it had no effect on atherosclerotic plaque formation49.  Additionally, a recent report 
demonstrated that bone marrow transplantation from p16INK4a deficient mice into Ldlr-/- mice 
on a high fat diet did not affect atherosclerotic plaque formation39. 
Although p16INK4a expression may be protective in early atherogenesis according to some 
studies, its role in promoting vascular cell senescence and dysfunction may have deleterious 
effects on already formed plaques.  Holdt et al demonstrated marked positive staining of 
p16INK4a and other CDK inhibitors in human atherosclerotic plaques.  They were able to 
estimate plaque stability by measuring expression levels of methylthioadenosine 
phosphorylase (MTAP), an enzyme involved in synthesizing polyamines critical for plaque 
stabilization.  Plaques with the lowest expression of MTAP exhibited the highest levels of 
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p16INK4a expression, suggesting that p16INK4a may play a role in plaque instability and 
rupture50. 
Given these observations, data in in vivo models supporting a role for CDKN2A in 
atherosclerosis has been somewhat controversial.  However, an important limitation to using 
mice to study this phenomenon is the possibility that the mouse CDKN2A locus, although 
very similar to that of humans, may be regulated differently.  Also, mice are not susceptible 
to atherosclerosis without being crossed to an ApoE-/- or Ldlr-/- strain and fed a high fat diet.  
Therefore, studying the pathophysiology of atherosclerotic plaque formation may not offer a 
completely representative picture, or always correspond with genetic data in humans. 
 
2.7  p16INK4a expression in vascular endothelial cells. 
 Although p16INK4a may play a protective role against proliferative arterial diseases such 
as atherosclerosis by limiting aberrant cellular proliferation, there are a number of 
physiologic changes that are associated with p16INK4a expression in other vascular 
compartments that may promote age-related diseases.  One tissue that responds to p16INK4a 
expression and undergoes senescence is the vascular endothelium51,52.  Endothelial cells 
provide a barrier between the luminal blood and highly procoagulant sub-endothelial proteins 
and are thus critical regulators of coagulation in both the arterial and venous circulation.  
Cellular senescence induced by p16INK4a expression is thought to promote vascular 
dysfunction by mediating phenotypic changes in endothelial cells31.  Similar to other cell 
types, endothelial cell senescence is marked by characteristic changes that distinguish it from 
quiescence, a non-terminal, reversible resting state.  First, senescent endothelial cells undergo 
a marked change in morphology adopting an enlarged, flattened shape compared to 
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proliferating cells which have a cobble-stone morphology in vitro53.  Another tell-tale 
signature of endothelial cell senescence is the expression of senescence-associated (SA) β-
galactosidase.  The detection of β-galactosidase at a pH of 6.0 is a common biomarker of 
senescence in many cell types.  Although the mechanism is not fully understood, it is thought 
that expression of acidic β-galactosidase is due to the presence of enlarged lysosomes and the 
accumulation of this enzyme in autophagic vacuoles within those lysosomes52.   
In addition to these distinct morphologic features that, in the presence of p16INK4a or p21 
overexpression, define endothelial cell senescence, other phenotypic changes have been 
reported that could have pathophysiologic consequences7.  In vitro, senescent endothelial 
cells secrete a variety of pro-inflammatory cytokines such as interleukin (IL)-6, IL-1α, IL-
1β, and IL-854.  Cytokine upregulation results in increased recruitment and binding of 
leukocytes to the vessel wall, which could support and sustain low level blood coagulation, 
particularly in the presence of tissue factor (TF)-bearing leukocytes.  Senescent endothelial 
cells also secrete more matrix metalloproteases (MMPs)8, which are involved in extracellular 
matrix degredation and are also able to cleave several chemokines and cytokines.  Another 
hallmark of vascular aging and endothelial cell senescence is reduced endothelial nitric oxide 
synthase (eNOS) production.  eNOS is critical for catalyzing the nitric oxide (NO)-
generating reaction in blood vessels.  NO is an important vasodilator and also potent inhibitor 
of platelet aggregation and leukocyte binding.  Loss of eNOS production during endothelial 
cell senescence results in reduced vasodilation, increased vessel rigidity, and increased 
platelet and leukocyte activation as a result of reduced NO bioavailability55-57.  Lastly and 
very importantly, increased expression of antifibrinolytic plasminogen activator inhibitor-1 
(PAI-1) is a biomarker of both replicative and stress-induced senescence8,9.  PAI-1 is a 
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powerful regulator of clot dissolution through inhibition of fibrinolytic proteases tissue and 
urokinase plasminogen activator (tPA and uPA, respectively) and is also an acute phase 
reactant and pro-inflammatory in nature58.  Therefore, increased production of PAI-1 by 
senescent vascular endothelial cells can lead to increased inflammation and the sustained 
presence of venous and arterial thrombi.  
 
2.8  p16INK4a expression in leukocytes. 
One of the initial reports establishing p16INK4a as a biomarker of physiologic aging came 
from data on p16INK4a expression in peripheral blood lymphocytes from humans of various 
ages4.  Expression of p16INK4a has also been found in other leukocytes, including monocytes 
and macrophages59.  One of the earliest phases of atherosclerotic plaque formation is the 
adherence of circulating monocytes to the vessel wall where they migrate into the sub-
endothelial spaces, differentiate in macrophages and ultimately consume oxidized low 
density lipoproteins and subsequently become foam cells60.  Monocytes and macrophages are 
also key players in the formation and resolution of venous thrombi through production of 
procoagulant TF and antifibrinolytic PAI-1, as well as phagocytosis of dead cells and 
promotion of proteolysis during thrombus resolution61.  Therefore, dysfunction of these cell 
types has important cardiovascular implications.   
Interestingly, two recent reports highlight the effects of cellular senescence on monocyte 
and macrophage function.  Merino et al demonstrated that elderly and chronically ill patients 
display a shift in their circulating monocyte immunophenotype from a CD14++CD16- 
predominant population to a CD14+CD16+ population62.  This expanded sub-population of 
monocytes were found to have increased SA β-galactosidase expression and reduced 
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telomere length compared to those from young and healthy controls, indicating that these 
cells had undergone senescence.  Additionally, the CD14+CD16+ sub-population of 
monocytes expressed increased vascular adhesion molecules and demonstrated increased 
adhesion to vascular endothelial cells.  They also were more sensitive to antigenic 
stimulation compared to controls and released more pro-inflammatory cytokines62.  These 
data suggest that senescent circulating monocytes are more pro-inflammatory and pro-
atherogenic compared to non-senescent monocytes.  
Further support for the idea that leukocyte senescence can modulate inflammatory 
responses comes from a recent report from Cudejko et al63.  This group found that 
macrophages from p16INK4a deficient mice displayed reduced expression of inflammatory 
cytokines IL-6 and TNF-α with increased expression of anti-inflammatory IL-R1.  These 
data suggest that p16INK4a expression has the ability to regulate monocyte and macrophage 
immunophenotyes and inflammatory function. 
 
2.9  Focus of this dissertation. 
While the anti-proliferative effects of p16INK4a may be important for reducing the risk of 
atherosclerotic disease, expression of p16INK4a in endothelial cells and leukocytes and the 
associated phenotypic changes discussed here could play a role in promoting other age-
related diseases in the vasculature.  Currently, there are virtually no publications studying the 
role of p16INK4a expression in the pathophysiology of venous thrombosis.  The upregulation 
of p16INK4a in the vasculature could be an important factor in the increased risk of venous 
thromoboembolism in the elderly.   
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Chapter 3. 
Overexpression of the Cell Cycle Inhibitor p16INK4a Promotes a  
Prothrombotic Phenotype Following Vascular Injury in Mice1 
 
3.1  Introduction 
Aging is an important risk fact1or for developing cardiovascular disease, and also the 
least understood1,2.  Venous thromboembolism (VTE) is characterized by the development of 
thrombi in the deep veins of the legs, which are prone to dislodging and embolizing to the 
lungs.  This condition accounts for 140,000-200,000 deaths each year in the U.S3,4.  The risk 
of developing VTE substantially increases with age and individuals over the age of 55 years 
have an annual incidence 5-7 times higher than young adults5.   While VTE in the younger 
population is often explained by mutations in hemostatic genes, mechanisms behind the 
increased risk of VTE in the elderly are less well understood.   
Senescence is one cellular phenomenon known to be associated with aging.   Cellular 
senescence is a stress-induced process, controlled by cell cycle inhibitors, which promotes an 
irreversible growth arrest6-9.  p16INK4a, a cell cycle inhibitor that promotes senescence, binds 
to cyclin-dependent kinases 4 and 6 to disrupt phosphorylation of the retinoblastoma protein, 
causing a G1 cell cycle arrest10.  Expression of p16INK4a increases with age in many tissues 
                                                
1 Cardenas JC, Owens AP, Krishnamurthy J, et al. Overexpression of the cell cycle inhibitor 
p16INK4a promotes a prothrombotic phenotype following vascular injury in mice. 
Arterioscler. Thromb. Vasc. Biol. 2011;31(4):827-833 
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and is a biomarker of aging11-14.  Furthermore, p16INK4a expression correlates with 
biomarkers of senescence, such as senescence-associated β-galactosidase expression, and 
expression is associated with gerontogenic activities such as smoking, physical inactivity and 
ad libitum feeding in humans or mice11,14.  In some tissues such as pancreatic beta cells, 
neural stem cells, and hematopoietic stem or progenitor cells, the age-induced increase in 
p16INK4a expression is associated with reduced cellular proliferation coupled with an impaired 
tissue response to injury15-17.  Additionally, senescent cells are thought to contribute to aging 
pathology through the production of cytokines (IL-6) that further promote inflammation and 
cellular dysfunction18. 
The contribution of senescence to disease in the venous circulation, and how this may be 
involved in age-related VTE or a possible prothrombotic phenotype, remains largely 
uncharacterized.  The aim of this study was to ascertain whether overexpression of p16INK4a 
modified venous thrombus formation in several well-defined animal models.  Our results 
demonstrate that p16INK4a overexpression augments vascular occlusion and delayed thrombus 
resolution relative to wild-type controls.  Furthermore, p16INK4a transgenic mice display 
enhanced thrombin generation, increased thrombin-antithrombin (TAT), and increased PAI-1 
levels when exposed to low-dose lipopolysaccharide (LPS).  Additionally, bone marrow 
transplantation between wild-type and p16INK4a transgenic mice demonstrated a substantial 
contribution of hematopoietic cells to this phenotype.  Overall, these results show that 
expression of p16INK4a is involved in promoting a prothrombotic environment in the venous 
vasculature. 
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3.2  Materials and Methods 
Mice 
All animal procedures were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee, UNC-Chapel Hill.  The bacterial artificial 
chromosome (BAC) transgenic mice overexpressing p16INK4a used in this study have been 
previously described15.  These animals harbor a single copy integration of 60 kb of the 
murine p16INK4a locus, and exhibit a 3-8 fold increase in p16INK4a expression in all tissues 
examined to date.  These animals do not overexpress other transcripts from the Ink4/Arf 
locus (i.e., p15INK4b and Arf) (data not included).  Mice were backcrossed to the C57BL/6 
background.  Experiments were done on male and female littermate progeny of indicated 
genotypes.  In all cases the mice were 6-8 weeks of age.  No differences were detected 
between males and females in the experiments performed. 
 
Real-Time PCR 
Quantitative Real-time PCR analysis was performed as previously described15.  Briefly, 
representative tissues were collected from transgenic and wild-type littermates used in 
thrombosis models for PCR analysis with the following primers.  Forward primer sequence: 
CGGTCGTACCCCGATTCAG.  Reverse primer sequence: 
GCACCGTAGTTGAGCAGAAGAG.  Expression of ARF was also quantified as a control 
with the following primers:  Forward primer sequence: 
TGAGGCTAGAGAGGATCTTGAGAAG.  Reverse primer sequence: 
GTGAACGTTGCCCATCATCATC.  
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Complete Blood Count 
Whole blood collected by cardiac puncture into EDTA tubes was analyzed for complete 
blood counts (CBC) by the UNC-CH Division of Lab Animal Medicine.  Blood samples 
were submitted from three mice per group. 
 
Prothrombin Time (PT)  
Prothrombin times were measured using a STart4 semi-automated hemostasis analyzer 
(Diagnostica Stago – Parispanny, NJ) by mixing equal volumes platelet poor plasma, calcium 
chloride (25 mM), and tissue factor (Innovin, 400 pM).  Data represents pooled plasma from 
three mice per group.   
 
Hemostasis Model 
Hemostasis was assessed as previously described19.  Briefly, wild-type and p16INK4a 
transgenic mice at 8 weeks of age were anesthetized with 2.5% tribromoethanol (Sigma 
Aldrich – St. Louis, MO, T48402) at 0.1 mL/g body weight.  The saphenous vein of 
anesthetized mice was exposed and transected with a 23-G needle.  Once bleeding stopped, a 
longitudinal cut was made in the vessel and the blood gently wiped away with kimwipes 
(Kimberly – Clark - Roswell, GA) until clotted.  The blood clot was disrupted using a 30-G 
needle and the blood gently wiped away.  Clot disruption was repeated every time hemostasis 
occurred and each hemostatic event was recorded using Chart software for 20 minutes.  
 For carotid artery thrombosis, the right common carotid artery was exposed after midline 
cervical incision.  A Doppler transonic flow probe (Transonic Systems, Ithaca, NY) was 
applied and connected to a flow meter (model T206, Transonic Systems, Ithaca, NY) 
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supplying a data acquisition system (PowerLab 4/30 model ML866, AD Instruments, 
Australia).  The carotid artery was dried and 10% FeCl3 (0.62 M FeCl3 on 0.5x0.5 mm filter 
paper) placed on the artery for 3 minutes, removed, and tissues washed 3 times with warm 
saline.  Following injury, blood flow was continuously monitored.  For saphenous vein 
thrombosis, the saphenous vein of the right leg was dissected and exposed, 5% FeCl3 (0.31 M 
FeCl3 on 0.5x2 mm filter paper) placed on the vein for 3 minutes, removed, and tissues 
washed 3 times with warm saline.  Blood flow was monitored auditorily by Doppler 
ultrasonic flow probe.  In both models, the TTO was the time between FeCl3 administration 
and lack of flow for 60 consecutive seconds.  Experiments were stopped at 45 minutes if no 
occlusion occurred.  Occluded vessels were excised and fixed in 10% formalin. 
 Thrombolysis was assessed in mice subject to FeCl3 carotid artery thrombosis.  After 5 
consecutive minutes of blood flow below 0.1 mL/min, mice were infused with TNKase (0.5–
5 mg/kg) through the saphenous vein intravenous catheter while continuously monitoring 
carotid blood flow.  
 
FeCl3 Vascular Injury 
The saphenous vein thrombosis model was performed as previously described19.  Briefly, the 
saphenous veins of anesthetized mice was exposed and dissected away from the saphenous 
artery.  A 0.5 x 2 mm piece of filter paper was soaked in 2.5% (N=4), 5% (N=5) or 10% 
(N=4) FeCl3 (Sigma Aldrich – F7134), and laid over the saphenous vein for 3 minutes.  The 
filter paper was then removed and the tissue was washed 3 times with warm saline.  Blood 
flow was monitored using a 20-MHz Doppler flow probe (Indus Instruments – Webster, TX).  
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Occlusion is defined as the absence of blood flow for one minute.  The time to flow 
restriction was defined as the time after injury at first cessation of blood flow.  
 
Rose Bengal Photochemical Vascular Injury 
Photochemical injury was performed as previously described20.  Briefly, both right and left 
saphenous veins of anesthetized mice were exposed.  The left saphenous vein was 
catheterized using catheters made in-house using pulled PE-10 tubing (Braintree Scientific -  
Braintree, MA).  Rose Bengal (Sigma Aldrich – R-3877), diluted to 30 mg/mL in normal 
saline, was infused through the catheter at a dose of 75 mg/kg through a gastight syringe 
(Hamilton Co. - Reno,NV).  Prior to infusion of Rose Bengal, a 1.75 mW green light (540 
nm) (Prizmatix – Southfield, MI) was directed 0.5 cm over the injury site on the right 
saphenous vein.  Light was applied to the vessel until a stable thrombus (defined as the 
absence of blood flow for 1 minute) was achieved. 
 
Thrombus resolution 
We developed a new method to measure thrombus resolution using the saphenous vein.  
Wild-type and p16INK4a transgenic mice (n=3 per genotype at each time point) were subjected 
to 10% FeCl3 injury to the saphenous vein.  The tissue was then washed 3 times with warm 
saline and a single ligature was placed upstream of the thrombus using a 8-0 monofilament 
polypropylene suture to prevent embolization and the leg was sutured closed.  Mice were 
sacrificed at various time points and the saphenous neurovascular bundle was removed and 
fixed overnight in 4% paraformaldehyde and paraffin embedded.  Five micron sections were 
cut and hematoxylin and eosin (H&E) stained to visualize the presence of a thrombus under 
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light microscopy.  Vessels were sectioned through and those sections showing the greatest 
area of occlusion were chosen for analysis.  Such sections typically occurred near the center 
of the injured vessel.  Images were analyzed using ImageJ software to calculate the percent 
of the vessel lumen that remained occluded by a thrombus. 
 
Low Dose Lipopolysaccharide (LPS) Treatment 
Wild-type and p16INK4a transgenic mice were treated with 2mg/kg intraperitoneal injection of 
LPS (Sigma L3012).  At various times (1, 3, and 5 hours), the mice (n=5 per genotype each 
time point) were anesthetized and 1mL of blood was collected from the inferior vena cava 
(IVC) into 3.8% sodium citrate at a ratio of 1:9 using a 25 gauge needle.  Whole blood was 
spun at 4,000 x g for 15 minutes and the platelet poor plasma was collected and stored at -
80°C until analyzed. 
 
Thrombin Generation 
  Thrombin generation was measured by calibrated automated thrombography (CAT) using 
Z-Gly-Gly-Arg-AMC fluorogenic substrate for thrombin (Diagnostica Stago, Parsippany, 
NJ) on a Fluoroskan Ascent fluorometer (ThermoLabsystem, Helsinki, Finland).  Mouse 
plasma was analyzed as previously described21.  Briefly, mouse plasma samples were pooled, 
diluted 1:4 in phosphate buffered saline and 80 µL of plasma was added to 20 µL low tissue 
factor (1 pM) reagent to initiate the reaction.  Variations in plasma color were accounted for 
using a α2-macroglobulin/thrombin calibrator reagent (Diagnostica Stago, Parsippany, NJ).  
Parameters were calculated by Thrombinoscope software version 3.0.0.29 (Thrombinoscope 
BV, Maastricht, Netherlands). 
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ELISAs 
TAT complexes were detected in mouse plasma using an Enzygnost TAT complex ELISA 
(Siemens – New York, NY, USA).  Plasma samples were diluted 1:10 in Enzygnost ELISA 
sample buffer.  PAI-1 was measured using an ELISA for mouse total PAI-1 from Molecular 
Innovations.  Fibrinogen was measured using an ELISA for mouse fibrinogen from 
Molecular Innovations (Novi, MI, USA).  Plasma samples from mice treated with LPS were 
diluted 1:40 and 1:160 for the PAI-1 and fibrinogen ELISAs, respectively.  Plasma samples 
from control mice were diluted 1:5 for both ELISAs.  All ELISAs were performed according 
to the company protocols and standard curves were generated using proteins supplied by the 
company. 
 
Immunohistochemistry 
Tissues were extracted and fixed overnight in 4% paraformadehyde.  Tissue embedding and 
cutting was performed in the UNC Linberger Comprehensive Cancer Center Animal 
Histopathology Core Facility.  Briefly, 5 micron sections were cut from paraffin blocks and 
antigen retrieval was performed in Target Retrieval Solution (Dako – Capinteria, CA, S1699) 
in a 95°C water bath. Slides were blocked for 1 hour in 1% BSA and stained with antibodies 
against p16INK4a (Santa Cruz Biotechnology - Santa Cruz, CA, sc-1661, 1:200 dilution), Ki67 
(Dako – M7249, 1:500 dilution), or PAI-1 (Santa Cruz Biotechnology – sc-8979, 1:250 
dilution) for 1 hour at room temperature in a humidity-controlled chamber.  Biotinylated 
secondary antibodies were obtained from Vector Laboratories.  Tissue slides were developed 
using the avidin-biotin complex (ABC) method using reagents and protocols obtained from 
Dako.  Negative control slides were stained simultaneously in the absence of primary 
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antibody.  Images were analyzed by taking a representative digital photograph of tissue from 
each mouse.  A grid was laid over the images using ImageJ software and percent positive 
grid boxes were calculated by counting the number of grid boxes containing a positively 
stained cell and dividing it by the total number of grid boxes on the image. 
 
 Bone marrow transplantation 
This procedure was performed as described previously22.  Briefly, mice were irradiated using 
a Cesium137 irradiator (JL Shepherd, San Fernando, CA) with a total of 11 Gy (two doses of 
550 rad, with a 4 hour rest) to abolish endogenous hematopoietic cells.  Bone marrow cells 
were isolated from donor mice22 and 1 x 107 cells were injected (100 µL) into the retro-
orbital sinus.  Four weeks after irradiation, recipient mice underwent FeCl3 injury to the 
saphenous vein to determine vascular occlusion times.  At termination, recipient mouse bone 
marrow was genotyped to verify successful repopulation of donor cells by polymerase chain 
reaction.  Expression of p16INK4a was compared to an IL-2 loading control.  
 
Statistics 
All statistical analyses were performed with Graphpad Prism.  All measurements are 
respresented as the mean ± standard error of the mean (SEM).  One-way ANOVA or 
Students T-test was performed where indicated.  One-way ANOVA was performed with a 
Tukey’s post-hoc test on measurements were indicated.  For two group comparison of 
parametric data, a student’s t-test was performed where indicated.   Values of p<0.05 were 
considered statistically significant. 
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3.3  Results 
p16INK4a transgenic and wild-type mice respond similarly in a hemostasis model.   
To determine the contribution of p16INK4a overexpression on potential hemostatic defects, 
mice initially underwent a model of saphenous vein hemostasis.  No difference was observed 
in the number of hemostatic clots formed over 20 minutes between transgenic (25.8 ± 3.4) 
and wild-type mice (25.8 ± 2.1, Figure 3.1A) or in the average time to hemostasis (33.5 ± 3.7 
sec and 36.6 ± 2.6 sec, respectively, Figure 3.1B).  Furthermore, no significant differences 
were observed in body weight, venous blood flow velocity, plasma prothrombin time (PT) 
and complete blood count (CBC) between the two groups of mice (Table 3.1).  These results 
suggest there is no obvious physical or hematologic phenotype in the p16INK4a transgenic 
mice at the ages studied. 
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Figure 3.1.  Hemostatic parameters in saphenous vein hemostasis model.  Hemostatic 
measurements were compared between wild-type and p16INK4a transgenic mice following 
blunt injury to the saphenous vein.  (A) The number of hemostatic clots formed and (B) the 
average time to stoppage of bleeding following serial clot disruption over 30 minutes.  Data 
not statistically significant. 
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Table 3.1.  Baseline parameters in wild-type vs. p16INK4a transgenic mice 
 
Baseline parameters that could potentially affect thrombosis were compared in wild-type and 
p16INK4a transgenic mice (± SD), as described in the Materials and Methods. 
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p16INK4a  transgenic mice show increased p16INK4a  expression and decreased cellular 
proliferation compared to wild-type.   
In order to determine the utility of this model for vascular studies, saphenous veins and 
other tissues from mice were characterized by real-time PCR and immunohistochemistry as 
to p16INK4a mRNA and protein expression, respectively.  In accord with prior results, mRNA 
analysis showed between 2- and 6 -fold increased expression of p16INK4a over wild-type 
littermates in heart, lung and spleen (Figure 3.2A).  Additionally, a six-fold increase in 
expression was noted in saphenous vein (Figure 3.2A).  Immunohistochemical staining 
showed ~30% positive staining for p16INK4a in kidney cells of transgenic mice, and ~3% 
positive staining for p16INK4a in wild-type mice (Figure 3.2B).  These results indicate that 
p16INK4a expression is elevated in most tissues, including larger veins, of the transgenic mice 
compared to littermate controls, and that this increased expression is associated with 
decreased proliferation, as determined by staining for the proliferation marker Ki67 (data not 
shown).  
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Figure 3.2.  p16INK4a  mRNA and protein levels in transgenic vs. wild-type mice.  (A) 
Real-time quantitative PCR was performed on organs collected from transgenic and wild-
type littermates.  Data are expressed as fold change in transgenic mice over wild-type, as 
described in Materials and Methods.  (B) p16INK4a protein was measured in kidneys of wild-
type (top panel) and transgenic (middle panel) mice by immunostaining as described in the 
Supplemental Materials and Methods. Images were quantified in ImageJ and expressed as 
percent positive staining for p16INK4a  (bottom panel). *denotes p<0.05 versus wild-type 
control by student t-test. 
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p16INK4a transgenic mice display a prothrombotic phenotype in a FeCl3 injury model.   
FeCl3 injury is a well-established mechanism for inducing thrombus formation in vivo23-
25.  We first demonstrated a dose-dependent effect of FeCl3 on the occlusion time in the 
saphenous vein, exposing wild-type mice to 2.5, 5, and 10% FeCl3 injuries to the saphenous 
vein (Figure 3.3A). 
Wild-type and p16INK4a transgenic mice were then subjected to FeCl3 (5%) injury to the 
saphenous vein.  The p16INK4a transgenic mice showed a significantly faster time to occlusion 
(13.1 ± 0.4 min) compared to wild-type mice (19.7 ± 1.1 min, Figure 3.3B).  Furthermore, 
the time to flow restriction was also measured.  The p16INK4a transgenic mice demonstrated 
faster times to flow restriction (6.4 ± 0.91 min) compared to wild-type controls (8.7 ± 0.54 
min, p<0.05, data not shown).  These results indicate overexpression of p16INK4a results in a 
prothrombotic phenotype following vascular injury. 
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Figure 3.3.  Overexpression of p16INK4a decreases time to occlusion in FeCl3 vascular 
injury model.  (A) Wild-type mice were subjected to increasing doses of FeCl3 to the 
saphenous vein to determine a dose-dependent effect on the occlusion time as described in 
the Materials and Methods *p<0.01 versus 2.5% FeCl3.  (B) Vascular occlusion times were 
compared between wild-type and p16INK4a transgenic mice after 5% FeCl3 injury to the 
saphenous vein.  The occlusion time represents the amount of time required to form an 
occlusive thrombus as described in the Materials and Methods.  * denotes p<0.01 versus 
wild-type control by student t-test. 
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p16INK4a transgenic mice display a prothrombotic phenotype in a photochemical injury 
model.   
The excitation of Rose Bengal to induce photochemical injury is another well-established 
mechanism for inducing thrombus formation in vivo26-28.  Upon photochemical injury to the 
saphenous vein, p16INK4a transgenic mice displayed a significantly faster time to occlusion 
(12.7 ± 2.0 min) when compared to wild-type mice (18.6 ± 1.9 min, Figure 3.4).  These 
results suggest the prothrombotic phenotype in mice overexpressing p16INK4a can be 
recapitulated in other vascular injury models. 
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Figure 3.4.  p16INK4a Transgenic mice have decreased time to occlusion in rose bengal 
photochemical vascular injury model.  Vascular occlusion times between wild-type and 
p16INK4a transgenic mice were compared following saphenous vein injury with 75 mg/kg 
Rose Bengal excited with 1.75 mW green light at 540 nm.  Occlusion times represent the 
amount of time required to form an occlusive thrombus.  *denotes p<0.05 versus wild-type 
control by student t-test. 
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p16INK4a transgenic mice exhibit delayed thrombus resolution.   
Venous thrombosis is characterized by the presence of unresolved thrombi in the lower 
extremities.  In order to study the effect of overexpressing p16INK4a on thrombus resolution, 
thrombi formed post-FeCl3 injury in wild-type and p16INK4a transgenic mice were monitored 
over time.  Mice were euthanized from 1 hour to 15 days post-FeCl3 injury and vascular 
ligation.  No significant differences in thrombus resolution were observed until 7 days after 
vascular injury.  By 10 days post-injury, all wild-type mice exhibited complete thrombus 
resolution, whereas p16INK4a transgenic mice maintained an average of 60% vessel occlusion.  
p16INK4a transgenic mice required additional time post-injury for thrombus resolution relative 
to wild-type controls (Figure 3.5 A).  Representative images show little difference in percent 
occlusion at one day (Figure 3.5 B) between p16INK4a transgenic and wild-type mice.  Black 
staining represents FeCl3 trapped within the thrombus.  At 10 days, we observed that residual 
FeCl3 was mostly contained within inflammatory macrophages and was present in the 
perivascular space of wild-type mice.  However, residual FeCl3 contained within 
macrophages was still present in the intravascular space of p16INK4a transgenic mice at 10 
days (Figure 3.5 B). These results demonstrate a defect in thrombus resolution with p16INK4a 
overexpression. 
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Figure 3.5.  p16INK4a  transgenic mice display defective thrombus resolution.  (A) 
Thrombus resolution was measured over time after 10% FeCl3 injury to the saphenous vein 
and stasis induced by ligation as described in the Materials and Methods. *denotes  p<0.05 
versus respective wild-type control by student t-test.  (B) Representative histologic images 
were analyzed using ImageJ software to determine percent occlusion (plotted in A).  (a) 
Wild-type at 1 day, (b) p16 Transgenic at 1 day, (c) Wild-type at 10 days, (d) p16 Transgenic 
at 10 days.  ■ - Wild-Type, ▲ - p16INK4a  Transgenic 
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p16INK4a transgenic mice display enhanced thrombin generation in response to LPS 
challenge.  
 Chronic inflammation and endothelial dysfunction have been linked to enhanced 
thrombin generation and the risk of venous thrombosis29-31.  LPS is known to activate the 
vascular endothelium and promote the formation of spontaneous thrombi32-35.  To study the 
effects of inflammation-induced coagulation, we exposed p16INK4a transgenic and wild-type 
mice to low dose LPS.  When analyzed by calibrated automated thrombography (CAT), 
plasma from the p16INK4a transgenic mice showed significantly shorter lagtime to initiation of 
thrombin generation and time to peak amount of thrombin generated at all time points post 
LPS treatment (Table 3.2).  The peak amount of thrombin generated was significantly higher 
in p16INK4a transgenic mice 3 and 5 hours after LPS treatment (Table 3.2).  The observed 
differences in thrombin generation demonstrates p16INK4a transgenic mice are able to 
generate more thrombin and have a prothrombotic phenotype when challenged with LPS.   
Mouse plasma was further analyzed to compare markers of coagulation and fibrinolysis. 
Fibrinogen was used as an acute phase reactant marker, no difference was detected by ELISA 
between wild-type and p16INK4a transgenic mice (Figure 3.6 A).  Circulating TAT complexes 
peaked at 3 hours post LPS treatment and subsequently declined to untreated baseline in both 
wild-type and p16INK4a transgenic mice (Figure 3.6 B).  While kinetic patterns were similar, 
transgenic mice had elevated TAT complex levels relative to wild-type at the 1 and 3 hour 
time points.  Induction of PAI-1 following LPS treatment was similar in pattern to TAT 
complex formation between wild-type and transgenic mice.  Peak PAI-1 levels were 
achieved at 3 hours post LPS treatment with a trending increase in PAI-1 in transgenic mice 
at this time point (Figure 3.6 C).  Immunostaining of livers collected 3 hours post LPS 
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treatment showed increased PAI-1 nuclear staining in p16INK4a transgenic mice, but not in 
wild-type mice (Figure 3.6 D).  These results suggest the altered thrombin generation 
parameters seen in the transgenic mice are not due to general differences in liver function, 
but to enhanced activation of specific coagulation proteins in p16INK4a transgenic mice.   
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Table 3.2.  Thrombin generation in wild-type (WT) vs p16INK4a transgenic (Tg)  
mouse plasma after LPS treatment 
 
Thrombin generation in plasma from mice treated with 2mg/kg LPS was measured using 
CAT, as described in the Supplemental Materials and Methods.  Data represents experiments 
performed in duplicate with 5 mice per group per time point (± SD).  *p<0.05 
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Figure 3.6.  Plasma analysis (A-C) and PAI-1 levels in liver (D) after LPS treatment.  
Plasma collected from the IVC after LPS treatment was analyzed using ELISAs for 
fibrinogen (A) and circulating TAT complexes (B) and PAI-1 (C).  *denotes p<0.05 versus 
respective wild-type control by student t-test.  (D) PAI-1 protein levels were measured in 
wild-type (top panel) and transgenic (middle panel) livers by immunostaining as described in 
the Supplemental Materials and Methods.  ❏ - Wild-Type, ■ - p16INK4a  Transgenic 
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p16INK4a expression in hematopoietic cells contributes to the observed prothrombotic 
phenotype.  
 In order to determine the relative contribution of p16INK4a expression in the 
hematopoietic cell compartment to the observed prothrombotic phenotype, bone marrow 
transplants were performed between transgenic and wild-type mice.  Following 
transplantation and recovery, mice were subjected to 10% FeCl3 injury to the saphenous vein.  
Consistent with our previous results (Figure 3.2 B), transgenic mice receiving transgenic 
bone marrow had retained their significantly reduced occlusion time (8.4 ± 0.48 min) when 
compared to wild-type mice receiving wild-type bone marrow (13.0 ± 0.79 min, Figure 3.7).  
Interestingly, transgenic mice receiving wild-type bone marrow displayed occlusion times 
similar to wild-type mice (12.8 ± 1.3 min), whereas wild-type mice receiving transgenic bone 
marrow displayed occlusion times similar to transgenic mice (9.5 ± 0.61 min, Figure 3.7).  
PCR results confirmed successful reconstitution by donor bone marrow cells (Figure 3.8).  
These results demonstrate that the effects of p16INK4a overexpression are, at least in part, 
mediated by hematopoietic cells. 
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Figure 3.7.  Vascular occlusion times are altered by bone marrow transplantation.  
Vascular occlusion times were compared between cohorts of bone marrow transplanted mice 
following injury of the saphenous vein with 10% FeCl3.  Occlusion time represent the 
amount of time required to form an occlusive thrombus.  *denotes  p<0.05 versus wild-type 
control cohort.  ** denotes p<0.05 versus transgenic control cohort.  # denotes p=0.08 versus 
wild type control cohort.  Statistical relevance was determined by one-way ANOVA with 
Tukey’s post-hoc analysis. 
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Figure 3.8.  PCR analysis of bone marrow transplantation recipients.  Quantitation of 
PCR performed on bone marrow collected from transplantation recipient mice to confirm 
successful repopulation with donor cells.  p16INK4a levels were compared to IL-2 and 
quantified using Image J software from a representative gel. 
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3.4 Discussion 
Senescence is a complex process that is thought to contribute to cardiovascular 
pathologies associated with aging.  Despite several reviews describing prothrombotic 
changes in senescent vascular endothelial cells36,37, no studies have described a venous 
thrombotic phenotype in mice overexpressing senescence-promoting genes.  In the current 
study, we examined parameters that define venous thrombotic potential in a mouse model of 
premature senescence through transgenic overexpression of the cell cycle inhibitor p16INK4a.  
As expected, the p16INK4a transgenic mouse exhibited increased expression of p16INK4a 
mRNA by real-time PCR analysis in all tissues tested.  Mice overexpressing p16INK4a exhibit 
normal basal hemostatic parameters as tested by CBC, PT, and an in vivo hemostasis model.  
This suggests that in the absence of vascular injury, overexpression of p16INK4a has no overt 
hemostatic consequences.  However, upon challenge in various vascular injury models, the 
p16INK4a transgenic mice displayed an obvious prothrombotic response. 
We have demonstrated a prothrombotic phenotype using two different vascular injury 
models.  Exposure of the vessel to FeCl3 is a type of biochemical injury that results in 
endothelial denudation and exposure of the subendothelium following lipid peroxidation38.  
This type of oxidative damage produces thrombi that are rich in platelets, but also contain red 
blood cells both encased in a dense fibrin meshwork indicating a role for soluble plasma 
factors driving thrombus formation39-41.  Rose Bengal is a fluorescein-based chemical that is 
excited to produce reactive oxygen species when exposed to green light at 540 nm.  This 
results in endothelial activation, although there is very little denudation, and is accompanied 
by rapid platelet adhesion.  Thrombi in this model are primarily composed of platelets and 
contain less fibrin implying this process is mostly platelet driven39.  The observation that 
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p16INK4a transgenic mice exhibit faster occlusion times in both of these models suggests there 
is likely a contribution by both soluble plasma factors and circulating cells.  The differences 
observed in the time to flow restriction may reflect altered rates of thrombus growth between 
wild-type and p16INK4a transgenic mice, which could be indicative of the potential to produce 
larger thrombi.   
In addition to more rapid rates of venous occlusion, p16INK4a transgenic mice also display 
impaired thrombus resolution.  The percent occlusion appears to be correlated with the 
sustaining of inflammatory infiltration.  It is possible that the inability to clear residual FeCl3 
from the intravascular space could be involved in further promoting thrombus formation.  
The increased production of PAI-1 observed in p16INK4a transgenic mice could also partly 
explain the thrombus resolution defect (Figure 3.6).  Evidence in the literature suggests 
increased circulating PAI-1 could have a negative impact on wound healing and fibrinolysis.  
Originally, Farrehi et al demonstrated enhanced fibrinolysis in PAI-1 deficient mice42.  
Eitzman et al found that transgenic mice overexpressing PAI-1 have more severe fibrosis 
following bleomycin-induced lung injury43. Zaman et al showed a profibrotic effect of PAI-1 
overexpression in the heart following myocardial infarction44.  Recently, McDonald et al 
demonstrated that aged mice display impaired thrombus resolution following stasis induced 
by inferior vena cava (IVC) ligation45.  In addition, they reported differences in various 
plasma and venous endothelium-associated proteins between aged and young wild-type 
mice45.  While an exact mechanism to account for the observed thrombus resolution defect in 
the aged mice is not yet known45, it is possible that changes in both the vessel wall and 
soluble plasma factors contribute, which may also be true of p16INK4a overexpressing mice.  
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To better understand differences in thrombus formation between p16INK4a transgenic and 
wild-type mice, coagulation parameters in mouse plasma samples were analyzed by CAT 
after inducing endothelial dysfunction with LPS.  Plasma analysis by CAT is sensitive to 
changes in coagulation factor levels46 and able to detect differences in thrombin generation 
parameters following a thrombotic event in human patients47.   Our results show that p16INK4a 
transgenic mice are able to initiate thrombin generation faster, achieve a higher peak amount 
of thrombin, and peak at a faster rate than wild-type controls.  Therefore, p16INK4a transgenic 
mice exhibit greater thrombin generation after LPS challenge compared to wild-type 
controls.  To complement these data, p16INK4a transgenic mice also showed elevated plasma 
levels of TAT and PAI-1 following LPS challenge.  These markers are commonly used to 
measure activation of coagulation (TAT)48,49 and endothelial activation (PAI-1)50,51. 
Yamamoto et al showed that aged mice had elevated induction of PAI-1 compared to young 
mice after LPS treatment, suggesting PAI-1 is important in endotoxin-induced thrombosis32.  
Since PAI-1 is both a marker of endothelial cell senescence and a potent fibrinolysis 
inhibitor,52 it could also participate in the delayed thrombus resolution seen in p16INK4a 
transgenic mice. 
To begin establishing a mechanism for the observed differences between wild-type and 
p16INK4a transgenic mice, bone marrow transplants were performed to determine the 
contribution of hematopoietic cells to the prothrombotic phenotype.  We found that wild-type 
mice given p16INK4a transgenic bone marrow had occlusion times very similar to that of 
transgenic controls.  Similarly, p16INK4a transgenic mice given wild-type bone marrow had 
occlusion times very similar to wild-type controls.  These data show that the prothrombotic 
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phenotype observed in mice overexpressing this gene is attributed to p16INK4a expression in 
hematopoietic cells.   
A growing body of in vitro evidence suggests senescence in the vascular endothelium 
may also participate in the transition to a procoagulant state during aging.  Senescence in the 
vascular endothelium is associated with an array of phenotypic changes with pathological 
consequences7,8.  These changes include upregulation of PAI-1, inflammatory cytokines 
(including interleukin-1α and interleukin-6), matrix metalloproteinases, and the down-
regulation of endothelial nitric oxide synthase36,37,53.  Thus, a role for the endothelium cannot 
be discounted and may warrant further investigation in this model. 
In contradistinction to the present data supporting a role for p16INK4a in venous 
thrombosis, a differing role for the expression of p16INK4a in arterial vascular diseases has 
been suggested.  Through genome-wide association studies, several groups have found a link 
between single nucleotide polymorphisms (SNPs) on chromosome 9p21.3 close to the 
p16INK4a open-reading frame and several atherosclerotic diseases (coronary artery disease, 
ischemic stroke, abdominal aortic aneurysm)54.  Liu et al have recently shown that 
individuals harboring the SNP genotypes associated with increased atherosclerotic risk 
exhibit decreased expression of p16INK4a and other INK4/ARF transcripts55.  Individuals at 
increased risk appear to differ in the expression and splicing of linear and circular forms of 
ANRIL, a long, non-coding RNA emanating from the INK4a/ARF locus thought to participate 
in INK4a/ARF expression56.  This observation suggests that decreased production of p16INK4a 
is associated with an increased risk of atherosclerosis, likely through limiting aberrant or 
excess proliferation of cellular components of atheromatous plaques.  This suggests 
expression of anti-proliferative molecules at the INK4a/ARF locus protects individuals from 
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atherosclerosis54,57.  In accord with this view, mice lacking p16INK4a have been shown to be 
more prone to vessel occlusion in a carotid artery injury model58.  Our current data, 
combined with prior work in the venous system36,37, suggest the intriguing possibility that 
age-induced p16INK4a expression and cellular senescence might play opposing roles with 
regard to thrombosis and atherosclerosis in the venous and arterial systems, respectively.    
Characterizing the link between age-related genetic changes and age-related 
cardiovascular diseases such as venous thrombosis is of paramount importance.  
Overexpression of proteins such as p16INK4a, which promote senescence and vascular 
dysfunction, could be the key age-related genetic change explaining cardiovascular maladies.  
Together, our results demonstrate that p16INK4a overexpression and cellular senescence 
contribute to a prothrombotic phenotype and defective thrombus resolution.  The results of 
this study provide the foundation for research on the effects of vascular senescence on 
venous thrombosis. 
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Chapter 4. 
Contribution of p16INK4a Expression in Monocytes and Macrophages to  
Thrombus Formation  
  
4.1  Introduction 
Age-related changes in hemostasis at the plasma and cellular levels contribute to the 
increased risk of cardiovascular disease in the elderly1,2.  Senescence is a process that occurs 
with aging, limiting cellular proliferation and likely evolved to protect against malignant 
transformation.  Cellular senescence is controlled at the molecular level by cell cycle 
inhibitors whose expression is stress-induced3-6.  Among the cell cycle inhibitors, p16INK4a is 
most commonly associated with aging, as expression of this gene is positive correlated with 
age7-10.  Age-dependent expression of p16INK4a has been studied in the context of vascular 
disorders and has been paradoxically implicated in both protection from and promotion of 
cardiovascular disease.  More specifically, p16INK4a is thought to play a protective role in 
arterial disease by exhibiting its antiproliferative effects.  In human studies, individuals 
harboring a single nucleotide polymorphism (SNP) on chromosome 9p21.3 that leads to 
decreased expression of p16INK4a have an increased risk of atherosclerosis10.  This suggests 
p16INK4a protects against atherogenesis by inhibiting the aberrant proliferation of smooth 
muscle cells and foam cells during atherosclerotic plaque formation. 
Conversely, a recent publication from our laboratory has shown that p16INK4a expression 
in mice promotes the development of age-related cardiovascular disease in the venous 
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circulation11.  Mice transgenically overexpressing p16INK4a displayed accelerated thrombus 
formation, delayed thrombus resolution and plasma hypercoagulability.  Adoptive transfer of 
this phenotype was observed in wild-type mice upon bone marrow transplantation from a 
p16INK4a transgenic donor.  Likewise, the prothrombotic phenotype was obliterated in 
transgenic mice receiving wild-type bone marrow.  These data suggest that p16INK4a 
expression in hematopoietic cells plays a critical role in venous thrombogenesis. 
The goal of this study was to further characterize the effect of p16INK4a expression on 
venous thrombosis in a model of venous stasis.  This thrombosis model is thought to be 
highly dependent on inflammatory cells originating in the hematopoietic compartment, thus 
an effect from p16INK4a in this cellular compartment should be observed. 
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4.2  Materials and Methods 
Mice 
All animal procedures were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee, UNC-Chapel Hill.  p16INK4a transgenic mice 
harbor a single copy integration of 60 kb of the murine p16INK4a locus, and exhibit a 3-8 fold 
increase in p16INK4a expression in all tissues examined to date.  These mice do not 
overexpress other transcripts from the INK4/Arf locus (i.e., p15INK4b and Arf).  Animals were 
bred on a C57BL/6J genetic background and backcrossed as detailed previously12.  All mice 
included in this study were males at 8 weeks of age. 
 
IVC Ligation 
Stasis-induced venous thrombosis by inferior vena cava (IVC) ligation is a well-described 
model to study DVT in mice13-15.  In this model, the IVC of anesthetized mice was exposed 
by laparotomy and dissected away from the aorta.  A single ligature was placed around the 
IVC just below the renal vein branching using a 8-0 prolene suture.  To achieve complete 
stasis, associated side and back branches were ligated or cauterized, respectively.  The 
laparotomy was closed by first suturing the peritoneum with an absorbable, 5-0 vicryl suture 
followed by suturing the skin with an 8-0 prolene suture.  Mice were euthanized 3 days post 
surgery and the IVC removed for analysis.  Thrombi were normalized to length of the 
effected vessel and data are expressed as weight/length. 
 
 
 
  83 
Immunohistochemistry 
Tissues were extracted and fixed overnight in 4% paraformadehyde.  Tissue embedding and 
cutting was performed in the UNC Linberger Comprehensive Cancer Center Animal 
Histopathology Core Facility.  Briefly, 5 micron sections were cut from paraffin blocks and 
antigen retrieval was performed in Target Retrieval Solution (Dako – Capinteria, CA, S1699) 
in a 95°C water bath. Slides were blocked for 1 hour in 5% serum derived from the species in 
which the secondary antibody was made and subsequently stained with antibodies against 
fibrin (Gift of Dr. Marshall Runge and Dr. Alisa Wolberg, 59D8, 1:1000), PAI-1 (sc-8979, 
Santa Cruz Biotech, Santa Cruz, CA, USA, 1:250), F4/80 (Serotec MCA497GA, Serotec, 
Oxford, UK, 1:250), Ly6G (14-5931-82, eBioscience, San Diego, CA, USA 1:500), 
thrombomodulin (MAB3894, R&D Systems, Minneapolis, MN, USA, 1:500) or TF (Gift of 
Novo Nordisk, Bagsvaerd, Denmark and Dr. Maureane Hoffman,1:1000) for 1 hour at room 
temperature in a humidity-controlled chamber.  Biotinylated secondary antibodies were 
obtained from Vector Laboratories.  Tissue slides were developed using the avidin-biotin 
complex (ABC) method using reagents and protocols obtained from Dako.  Negative control 
tissue sections were stained simultaneously in the absence of primary antibody.  To analyze 
immunostained tissues, images were collected at 10x magnification (three images per tissue 
section) and the average number of positive pixels per image was quantified using 
Photoshop. 
 
Monocyte/macrophage depletion 
Liposomes packaged with clodronate or PBS were purchased from ClodronateLiposomes.org 
(Vrije Universiteit, Netherlands).  Monocyte and macrophage depletion using clodronate 
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liposomes was performed as previously described16,17.  Briefly, liposomes (1mg/mL) were 
injected twice intravenously via the retro-orbital plexus in a 0.2 mL volume.  The first 
injection was 48 hours prior to IVC ligation surgery and the second injection was on the day 
of surgery.  Depletion was confirmed by complete blood count (CBC) and by 
immunoblotting for the monocyte/macrophage marker F4/80 in the spleen. 
 
Western Blotting Analysis 
Tissues were homogenized using a PowerGen125 homogenizer (Fisher Scientific, Waltham, 
MA) in cold lysis buffer composed of 50 mM Tris, 150 mM NaCl, 1% Triton X-100, 1% 
deoxycholate, 1 mM EDTA, 0.1% sodium dodecylsulfate (SDS), 1 mM 
phenylmethanesulfonyl fluoride (PMSF), 5 mg/mL aprotinin, and 5 mg/mL leupeptin.  
Homogenized tissues were kept on ice for 30 minutes and centrifuged at 10,000 x g for 20 
minutes at 4°C to separate insoluble material.  Protein concentrations were measured using 
the BioRad Protein DC assay (BioRad, Hercules, CA, USA).  Protein samples were separated 
on a 7.5% SDS polyacrylamide gel and electrophoretically transferred to a nitrocellulose 
membrane.  Membranes were rinse in de-ionized water and non-specific binding was blocked 
using 5% non-fat dry milk in PBS containing 0.1% Tween 20 (PBST) for 1 hour at room 
temerature.  Following blocking, the membranes were washed 3 times for 5 minutes in 
PBST.  Membranes were incubated overnight at 4°C in primary antibody prepared in 2.5% 
non-fat dry milk on a rocker.  Membranes were washed in PBST and incubated in secondary 
antibody prepared in 2.5% non-fat dry milk for 1 hour at room temperature.  Membranes 
were washed in PBST and developed by chemiluminescence and exposure to X-ray film.  
The primary antibodies were rat anti-mouse F4/80 (1:2000) (Serotec, MCA497GA, Serotec, 
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Oxford, UK) with a peroxidase-conjugated secondary antibody used at a 1:4000 dilution and 
goat anti-human GAPDH (1:1000) (Santa Cruz Biotechnology, sc-48167, Santa Cruz, CA, 
USA) with a peroxidase conjugated secondary antibody used at a 1:3000 dilution.  
 
Statistical Methods 
All statistical analyses were performed with Graphpad Prism.  All measurements are 
respresented as the mean ± standard error of the mean (SEM).  Student’s T-tests were 
performed to determine statistical relevance where indicated.  Values of p<0.05 were 
considered statistically significant. 
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4.3  Results 
Effect of p16INK4a expression on stasis-induced thrombus formation. 
Mice overexpressing p16INK4a and wild-type littermate controls were compared in a 
model of stasis-induced thrombosis (n=4 per group).  We found significantly larger thrombi 
in p16INK4a transgenic mice after a 3 day ligation compared to wild-type controls (Figure 4.1). 
 
Histologic analysis of stasis-induced thrombi in wild-type and p16INK4a transgenic mice. 
Fixed and paraffin embedded thrombi and associated vessel wall were analyzed 
histologically to determine any protein or cellular composition changes that may contribute 
to the increase in thrombus formation.  No statistical differences were detected in fibrin 
content, tissue factor (TF), thrombomodulin (TM), plasminogen activator inhibitor (PAI-1), 
or neutrophil-associated LY6G levels (Figure 4.2A).  However, a significant increase in the 
monocyte/macrophage marker F4/80 was observed in mice overexpressing p16INK4a (Figure 
4.2B). 
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Figure 4.1.  Mice overexpressing p16INK4a have larger thrombi in a model of stasis-
induced thrombosis.  Wild-type and p16INK4a transgenic mice (n=4 mice per group) 
underwent inferior vena cava (IVC) ligation to promote stasis-induced thrombosis.  After a 3 
day ligation, thrombi were extracted and analyzed for length and weight.  Thrombus mass 
was determined by dividing thrombus weight by length.  Data are represented as weight (mg) 
over length (mm). * denotes p<0.05 
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Figure 4.2.  Immunostaining analysis of IVC containing thrombus.  (A) Thrombosed 
IVCs were analyzed by immunohistochemistry to determine relative expression levels of 
several vessel wall and thrombus-associated proteins and inflammatory cells.  Quantification 
was performed either in Photoshop or manually by counting positive cells and are expressed 
in number of positive pixels or number positively staining cells.  * denotes p<0.05  (B) 
Representative images from F4/80 staining of thrombosed vessels. 
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Clodronate liposomes successfully deplete monocytes and macrophages. 
Depletion of circulating monocytes by clodronate liposomes was confirmed by CBC of 
whole blood at the time of IVC collection.  We detected approximately 50% depletion of 
monocytes in whole blood (Figure 4.3A).  Depletion of tissue macrophages by clodronate 
liposomes was confirmed by immunoblot of the spleen at the time of IVC collection.  The 
representative blot is shown with quantification by densitometry detecting approximately 45-
50% depletion of tissue macrophages (Figure 4.3B). 
 
Enhanced stasis-induced thrombosis is normalized to wild-type upon depletion of 
monocytes and macrophages. 
To determine the contribution of p16INK4a expression in monocytes and macrophages in 
this model, both wild-type and p16INK4a transgenic mice were treated with clodronate 
liposomes 48 hours prior to, and on the day of IVC ligation surgery to deplete these cell 
types.  We observed that while all mice receiving clodronate had larger thrombi when 
compared to those receiving PBS, thrombi from mice overexpressing p16INK4a were then the 
same size as wild-type controls (Figure 4.4). 
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Figure 4.3.  Clodronate liposomes deplete circulating monocytes and tissue 
macrophages.  (A) Depletion of circulating monocytes was confirmed by blood count 
analysis using a Hemavet HV950FS.  * denotes p<0.05  (B) Depletion of tissue macrophages 
was confirmed by homogenization and western blot analysis from spleens of liposome 
treated mice.  Top panel shows a representative immunoblot of F4/80 macrophage marker 
expression in the spleens.  Bottom panel shows quantification of immunoblot by 
densitometry.  * denotes p<0.01 
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Figure 4.4.  Monocyte and macrophage depletion normalizes p16INK4a transgenic and 
wild-type stasis-induced thrombus size.  IVC ligation thrombosis model was repeated in 
the presence of clodronate or control liposomes.  Thrombus sizes show no difference 
between wild-type and transgenic mice.  Data represented as thrombus weight (mg) over 
length (mm). 
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4.4 Discussion 
Data on the contribution of p16INK4a expression to venous thrombosis in the elderly is 
largely non-existent.  Previously, we have shown that expression of p16INK4a in 
hematopoietic cells is involved in promoting venous thrombosis in mouse models11.  In this 
study, we use a stasis-induced thrombosis model to further characterize the effect of p16INK4a 
expression in inflammatory cells on promoting this process. 
We found that mice overexpressing p16INK4a have significantly larger thrombi than wild-
type after 3 days of IVC ligation (Figure 4.1).  This finding confirmed our previous data 
showing p16INK4a transgenic mice display a prothrombotic phenotype.  Qualitative histologic 
analysis by H&E staining showed no apparent differences in general composition or 
proteinaceous content between transgenic and control mice (data not shown).  Upon further 
analysis by immunohistochemistry, we found no significant differences in endothelial-
derived proteins such as PAI-1, TF, or TM.  There are currently no data to suggest that 
elevated TF is a phenomenon associated with aging or senescence so these findings were not 
surprising.  We previously found increases in circulating and liver-derived PAI-1 following 
endotoxemia.  Elevated PAI-1 is a marker of both aging and endothelial cell senescence, 
however it does not appear to be playing a role in early stasis-induced thrombogenesis.  
Reduced TM has recently been found to exacerbate the response to endotoxin treatment in 
aged mice18.  While we found a slight trend in TM reduction in p16INK4a overexpressing mice 
after IVC ligation, staining for TM in lungs for both untreated and LPS treated mice from an 
unrelated experiment showed no difference in TM expression between p16INK4a transgenic 
and control mice (data not included).  This further confirmed our previous bone marrow 
transplantation data showing hematopoietic expression and not endothelial expression of 
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p16INK4a was responsible for driving this phenotype.  Additionally, no difference in fibrin 
content by immunostaining was observed between p16INK4a transgenic and wild-type control 
mice (Figure 4.2A).   
When staining for the presence of inflammatory leukocytes, no quantifiable difference 
was detected in neutrophil levels as measured by expression of the neutrophil surface marker 
Ly6G (Figure 4.2A).  In the natural history of venous thrombosis, neutrophils are the first 
leukocytes detected in the thrombus, present as early as 2 hours following IVC ligation19.  
Neutrophils are thought to play a role in the clearance of early forming thrombi rather than 
promoting thrombogenesis, as data from Varma et al showed that neutrophil depletion led to 
increased thrombus size20.  As no difference in neutrophil infiltration was apparent in our 
model, we conclude that the absence of neutrophils to promote early thrombus clearance was 
not the cause of greater thrombus size with p16INK4a overexpression. 
Conversely, immunostaining for F4/80 monocyte/macrophage antigen showed significant 
increases in monocyte and macrophage infiltration in thrombi from p16INK4a overexpressing 
mice compared to wild-type (Figure 4.2).  Macrophage responses during thrombosis occur 
following neutrophil infiltration, with 3 days post thrombogenesis likely representing one of 
the earliest points during infiltration, followed by linear increases in macrophage presence 
over time during thrombus resolution21.  Macrophages are recruited to the thrombus in 
response to fibrinogen as well as toll-like receptors and selectin expressed on neutrophils and 
damaged endothelial cells.  Macrophages play an important role in scavenging dead cells and 
promoting proteolysis and wound healing by releasing proteases, growth factors and 
cytokines21.  However, macrophages also express procoagulant TF and antifibrinolytic PAI-
1, therefore an overabundance of these cells, especially early on in thrombus formation might 
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exacerbate thrombosis by propagating thrombin generation and inhibiting plasminogen 
activation.  The increase in monocytes/macrophages seen in our model align with our 
previous findings that thrombus formation was enhanced by p16INK4a expression in the 
hematopoietic compartment.  
To determine the role of monocytes and macrophages in thrombus formation, we 
repeated the 3 day IVC ligation studies in p16INK4a transgenic and wild-type littermate control 
mice after reduction of monocytes and macrophages with clodronate liposomes.  Cell 
reduction was confirmed by measuring circulating monocytes in whole blood by Hemavet 
analysis and also by measuring F4/80 surface marker expression in spleens, an organ known 
to be abundant in macrophages (Figure 4.3).  We found that the thrombi extracted from 
monocyte/macrophage-depleted mice were indistinguishable in size between p16INK4a 
overexpressing and wild-type control mice (Figure 4.4).  Mice treated with PBS control 
liposomes showed a similar increase in thrombus size in p16INK4a transgenic mice to those 
data reported in the absence of liposome treatment (n=2 per group, data not shown).  These 
data suggest that p16INK4a expression in monocytes and macrophages is likely to be the 
driving force behind increased venous thrombosis in p16INK4a overexpressing mice.  Had the 
effect been mediated by neutrophils or any other cell type or even circulating protein factor 
level, we would not have succeeded in normalizing the thrombus sizes. 
One limitation of this study is that we collected data at only one time point during venous 
thrombosis.  Our previous data showed delayed venous thrombus resolution over time in 
p16INK4a transgenic mice after FeCl3 injury.  Thus, it would be very important and interesting 
to see what is occurring at the earlier and later time points in this model, to determine if there 
is sustained elevation of macrophages and how this affects thrombus resolution. 
  95 
Another limitation is that we found similar results upon depletion of monocytes and 
macrophages as Valmar et al found when depleting neutrophils.  Mice treated with 
clodronate liposomes have much larger thrombus mass than those untreated or treated with 
control liposomes.  While there was no difference in neutrophil counts that would suggest 
unintended phagocytosis of liposomes by these cells, this could be explained by the lack of 
early thrombus clearance by monocytes trapped within the growing thrombus.  Additionally, 
the effects of free clonodronate to the circulation are unknown.  It is thought that upon 
phagocytosis of liposomes, any free clondronate released upon cellular apoptosis is rapidly 
cleared by the kidneys22.  However, any effects exhibited prior to clearance are unexplored.   
These data remain preliminary as a prior attempt at performing this experiment using a 
three-dose treatment strategy resulted in post-surgical death of all animals, leaving a cohort 
of only 3 animals per group receiving 2 doses of clodronate liposomes.  More mice are 
required to repeat this experiment with treatment of both clodronate and PBS control 
liposomes.  Additionally, repeating the IVC ligation studies in monocyte/macrophage 
specific p16INK4a knock-out or p16INK4a overexppressing mice would more directly test our 
hypothesis that expression of this protein in monocytes and macrophges is responsible for the 
prothrombotic phenotype.   
In conclusion, we have found that p16INK4a expression in monocytes and macrophages 
does contribute to venous thrombosis.  It remains unclear whether this is simply due to 
enhanced recruitment of these cells to the thrombus or if perhaps these cells also have an 
altered phenotype making them more procoagulant, proinflammatory, and antifibrinolytic 
than wild-type counterparts.  Interestingly, recent literature describes phenotypic changes in 
senescent monocytes that could have important pathophysiologic consequences.  In healthy 
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individuals, the vast majority of circulating monocytes express CD14++CD16- surface 
antigens, however elderly individuals and those with chronic illnesses show expansion of a 
CD14+CD16+ monocyte population.  These cells exhibit similar characteristics to senescent 
cells and have increased antigenic sensitivity, more proinflammatory secretions, increased 
expression of vascular adhesion molecules, and increased endothelial cell adhesion23.  This 
suggests the interesting possibility that monocytes and macrophages from p16INK4a 
overexpressing mice could be phenotypically distinct from wild-type control cells, and that 
p16INK4a upregulation in aging humans could be promoting this cellular population shift.  
This data strongly suggests that p16INK4a expression in monocytes and macrophages is 
important for venous thrombosis.   
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Chapter 5. 
Vascular Endothelial Cell Senescence is Associated with a Prothrombotic Phenotype 
 
5.1  Introduction 
Venous thrombosis is a dynamic process involving dysregulation of pro and 
anticoagulant processes in the blood and vessel wall.  The vascular endothelium is an 
important tissue in both the venous and arterial circulation, providing the barrier between the 
luminal blood and intima of the vessel wall.  As the only non-circulating cell type in direct 
contact with the flowing blood, endothelial cells are pivotal in preventing thrombosis while 
still maintaining hemostasis1,2.  Anticoagulant in nature, endothelial cells produce an array of 
proteins designed to inhibit the generation of thrombin such as heparin and dermatan sulfates, 
which enhance the activity of circulating antithrombin3,4, and also thrombomodulin and its 
cofactor endothelial protein C receptor (EPCR), which activate anticoagulant protein C upon 
binding of thrombin5,6.  In addition to inhibiting thrombin generation, endothelial cells 
express tissue factor pathway inhibitor (TFPI), a key inhibitor of tissue factor (TF)7, which is 
the most potent initiator of extrinsic blood coagulation.  Endothelial cells are also key 
mediators of fibrinolysis through production of both tissue and urokinase plasminogen 
activators (tPA and uPA) and the physiologic inhibitor of these molecules, plasminogen 
activator inhibitor (PAI-1)8-10.  Additionally, expression of adhesion molecules, nitric oxide, 
and prostacyclin make endothelial cells key mediators of leukocyte binding, platelet 
activation/inactivation, and vasoconstriction/dilation11-14.  Thus, the vascular endothelium is a 
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very important regulator of events involving the initiation, propogation and dissolution of 
blood clots.  
Endothelial dysfunction can cause the endothelium to go from a quiescent, anticoagulant 
surface to one that is procoagulant and is thought to be a consequence of human aging15.  
Endothelial dysfunction is associated with increased expression of procoagulant TF16, 
antifibrinolytic PAI-117, proinflammatory cytokines18 with a concomitant decrease in 
anticoagulant thrombomodulin19 and the vasodialtor nitric oxide20,21.  All are changes that 
can contribute to venous thrombogenesis.  Endothelial dysfunction during aging is not well 
understood, however one potential cause is cellular senescence. 
Senescence is a process through which mitotic division is irreversibly halted either by 
cellular sensing of telomere shortening or through stress-induced expression of cell cycle 
inhibitors.  Vascular endothelial cells will undergo senescence in response to a variety of 
stressors including inflammation or oxidative damage through upregulation of the cell cycle 
inhibitor, p16INK4a22,23.  p16INK4a functions by binding to cyclin-dependent kindases (CDK) 4 
and 6, disrupting phosphorylation of the retinoblastoma protein (Rb) by these kinases, 
causing a G1 cell cycle arrest24.  Senescence in the vascular endothelium is associated with 
an array of phenotypic changes with possible cardiovascular consequences25,26.  These 
include upregulation of PAI-1, multiple inflammatory cytokines, and matrixmetalloproteases 
(MMPs)25.  These changes, combined with other effects of aging in endothelial cells 
mentioned previously, can contribute to venous thrombotic complications in the elderly.  The 
aim of this study was to examine the phenotypic changes that occur when vascular 
endothelial cells undergo senescence and how this affects blood coagulation on the 
endothelial cell surface. 
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5.2  Materials and Methods 
Cell Culture 
Human umbilical vein endothelial cells (HUVEC) pooled from multiple donors were 
obtained from Lonza.  HUVEC were maintained in endothelial basal medium (EBM-2) 
supplemented with 0.2% FBS, 0.4% hFGF-B, 0.1% VEGF, 0.1% IGF-1, 0.1% Ascorbic 
Acid, 0.1% hEGF, 0.1% GA-1000, 0.1% heparin, 1% L-glutamine, and 1% 
penicillin/streptomycin solution.  HUVEC were grown in a humidified chamber at 37°C with 
5% CO2. 
 
Senescence-associated (SA) β-Galactosidase Activity Assay 
SA β-galactosidase activity staining was performed using a kit (Cell Signaling, 9860S, 
Beverly, MA, USA).  Briefly, HUVEC were grown to 80% confluency in a 6 well plate, 
washed with PBS and fixed with 2% formaldehyde and 0.2% glutaraldehyde.  Cells were 
washed and stained with β-galactosidase solution containing 5-bromo-4-chloro-3-indolyk-
βD-galactopyranoside (X-gal), potassium ferrocyanide, and potassium ferricyanide in citric 
acid/sodium phosphate.  
 
Quantitative Polymerase Chain Reaction (PCR) 
RNA isolation from HUVEC was performed using Trizol reagent (Invitrogen) according to 
the manufacturer’s specifications.  RNA was reverse transcribed (2 µg) with Moloney murine 
leukemia virus reverse transcriptase (Biorad, iScript™) according to the manufacturer’s 
instructions.  Initial denaturation was performed at 95°C for 5 min followed by cDNA 
amplification over 40 cycles (denaturation at 95°C for 20 sec, annealing at 55°C for 1 min, 
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elongation at 68°C for 30 sec) using an Eppendorf thermocycler.  SYBR Green probe was 
used for quantitative reactions (Applied Biosystems, Foster City, CA, USA).  Sequences for 
the primers used were: HPRT forward, TGG AGT CCT ATT GAC ATC GCC AGT; HPRT 
reverse, AAC AAC AAT CCG CCC AAA GGG AAC; GAPDH forward, ACC ACA GTC 
CAT GCC ATC AC; GAPDH reverse, TCC ACC ACC CTG TTG CTG TA; PAI-1 forward, 
5’-AAT CAG ACG GCA GCA CTG TC-3’; PAI-1 reverse, 5’CTG AAC ATG TCG GTC 
ATT CC-3’.  Primers for p16INK4a were purchased from Santa Cruz (Santa Cruz 
Biotechnology, sc-36143-PR, Santa Cruz, CA, USA).  Ct vales were averaged for each 
reaction and expression was normalized to HPRT or GAPDH loading control.  Relative 
expression was determined with the 2-ΔΔCt method, normalizing expression of passage 3 
HUVEC to 1. 
 
Western Blotting Analysis 
Confluent cells were lysed in cold lysis buffer composed of 50 mM Tris, 150 mM NaCl, 1% 
Triton X-100, 1% deoxycholate, 1 mM EDTA, 0.1% sodium dodecylsulfate (SDS), 1 mM 
phenylmethanesulfonyl fluoride (PMSF), 5 mg/mL aprotinin, and 5 mg/mL leupeptin.  Cell 
lysates were kept on ice and centrifuged at 10,000 x g for 20 minutes at 4°C to separate 
insoluble material.  Protein concentrations were measured using the BioRad Protein DC 
assay (BioRad, Hercules, CA, USA).  Protein samples were separated on a 7.5% SDS 
polyacrylamide gel and electrophoretically transferred to a nitrocellulose membrane.  
Membranes were rinse in de-ionized water and non-specific binding was blocked using 5% 
non-fat dry milk in PBS containing 0.1% Tween 20 (PBST) for 1 hour at room temerature.  
Following blocking, the membranes were washed 3 x 5 minutes in PBST.  Membranes were 
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incubated overnight at 4°C in primary antibody prepared in 2.5% non-fat dry milk on a 
rocker.  Membranes were washed 3 x 5 minutes in PBST and incubated in secondary 
antibody prepared in 2.5% non-fat dry milk for 1 hour at room temperature.  Membranes 
were washed 3 x 5 minutes in PBST and developed by chemiluminescence and exposure to 
X-ray film.  The primary antibodies were used at a 1:1000 dilution and secondary antibodies 
at a 1:3000 dilution unless otherwise noted.  Primary antibodies used for these experiments 
were p16INK4a (Santa Cruz Biotechnology, sc- 468, Santa Cruz, CA, USA), TM (Abcam, 
ab6980, Cambridge, MA, USA), EPCR (JNK1494, Gift of Dr. Chuck Esmon, primary 
1:2000, secondary 1:6000), PAI-1 (Molecular Innovations, ASHPAI, Novi, MI), and 
GAPDH (Santa Cruz Biotechnology, sc-48167, Santa Cruz, CA, USA). 
 
Clot formation assay 
Clot formation was initiated on the surface of HUVEC in a 96-well plate by adding calcium 
(10 mM, final) and normal pooled plasma (87%, final).  Clot formation was monitored by 
turbidity at 405 nM for 1 hour at 37°C using a SpectraMax Plus 384 (Molecular Devices, 
Sunnyvale, CA, USA) plate reader. 
 
Thrombin Generation 
Thrombin generation was measured by calibrated automated thrombography (CAT) using Z-
Gly-Gly-Arg-AMC fluorogenic substrate for thrombin (Diagnostica Stago, Parsippany, NJ) 
on a Fluoroskan Ascent fluorometer (ThermoLabsystem, Helsinki, Finland).  Normal pooled 
human plasma (80 µL) was added to the washed HUVEC monolayer to initiate the reaction. 
Variations in plasma color were accounted for using a α2-macroglobulin/thrombin calibrator 
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reagent (Diagnostica Stago, Parsippany, NJ).  Parameters were calculated by 
Thrombinoscope software version 3.0.0.29 (Thrombinoscope BV, Maastricht, Netherlands). 
 
Clot structure analysis by laser scanning confocal microscopy 
 Clot structure was analyzed as described previously27.  HUVEC were plated in Lab-Tek II 
chamber slides (Nalge Nunc International) at a density of 33,000 cells/well).  Once cells 
reached 80% confluency, clots were formed on the washed cell surface using normal pooled 
plasma (87%, final) and calcium (10 nM, final) in the presence of AlexaFluor-488-labeled 
fibrinogen (10ug/150uL volume, 3.2% of total fibrinogen, Gift of Dr. Alisa Wolberg).  A 
clotting assay was performed in parallel on cells plated at the same time in a 96 well plate to 
ensure a constant final turbidity was achieved prior to microscopy analysis.  Clots were 
imaged using a Zeiss LSM5 Pascal laser scanning confocal microscope under the conditions 
previously described27. 
Density of the fibrin network was analyzed in ImageJ.  A random grid of 2 pixel crosses was 
placed over deconvolved z-stack images and the fibers that crossed through the intersection 
of those crosses was counted manually and divided by the number of crosses on the image. 
 
TF activity 
TF activity on HUVEC surface was measured by incubating washed cells with calcium (5 
mM), FVIIa (100 pM) and FX (135 nM) for 5 minutes.  Generation of FXa was then 
measured by cleavage of a chromogenic substrate (0.5 mM) detected at 405 nm for 30 
minutes.  Cells were stimulated with 3 ng/mL TNF-α 4 hours prior to TF activity assay.  This 
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is assay was done in the presence of anti-TF antibody (10 µg/mL, gift Dr. Nigel Mackman) 
or control IgG (10 µg/mL) which was added 5 minutes prior to assay reagents. 
 
Activated Protein C Generation 
The ability to generate APC on HUVEC surface was measured by incubating washed cells 
with thrombin (10 nM), and protein C (0.5 µM) in buffer containing 1% bovine serum 
albumin, 3 mM CaCl2 and 0.6 mM MgCl2 for 30 minutes.  The reaction was then quenched 
by the addition of heparin (2 U/mL) and antithrombin (0.5 µM).  The generation of APC was 
then monitored by cleavage of a chromogenic substrate (0.15 mM) detected at 405 nM for 30 
minutes.  This is assay was done in the presence of anti-TM antibody (20 µg/mL, gift Dr. 
Chuck Esmon) or control IgG (20 µg/mL) which was added 5 minutes prior to assay 
reagents. 
 
Immunohistochemistry 
Tissues were extracted and fixed overnight in 4% paraformadehyde.  Tissue embedding and 
cutting was performed in the UNC Linberger Comprehensive Cancer Center Animal 
Histopathology Core Facility.  Briefly, 5 micron sections were cut from paraffin blocks and 
antigen retrieval was performed in Target Retrieval Solution (Dako – Capinteria, CA, S1699) 
in a 95°C water bath. Slides were blocked for 1 hour in 5% serum derived from the species in 
which the secondary antibody was made and subsequently stained with an antibody against 
thrombomodulin (MAB3894, R&D Systems, Minneapolis, MN, USA, 1:500) for 1 hour at 
room temperature in a humidity-controlled chamber.  Biotinylated secondary antibodies were 
obtained from Vector Laboratories.  Tissue slides were developed using the avidin-biotin 
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complex (ABC) method using reagents and protocols obtained from Dako.  Negative control 
tissue sections were stained simultaneously in the absence of primary antibody.  To analyze 
immunostained tissues, images were collected at 10x magnification (three images per tissue 
section) and the average number of positive pixels per image was quantified using 
Photoshop. 
 
Statistical Methods 
All statistical analyses were performed with Graphpad Prism.  All measurements are 
respresented as the mean ± standard error of the mean (SEM).  Student’s T-tests were 
performed to determine statistical relevance where indicated.  Values of p<0.05 were 
considered statistically significant. 
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5.3  Results 
Serial passaging induces p16INK4a upregulation and cellular senescence in endothelial 
cells. 
Human umbilical vein endothelial cells (HUVEC) were serial passaged to induce 
replicative senescence in vitro.  HUVEC were compared at early passage (3), middle passage 
(6) and late passage (9) for markers of endothelial senescence.  We observed significant 
increases in SA β-galactosidase expression in late passage HUVEC when compared to early 
and middle passages (Figure 5.1A).  This was accompanied by elevated p16INK4a mRNA and 
protein levels (Figure 5.1B).  Plasminogen activator inhibitor (PAI-1) is a known marker of 
senescence specific to endothelial cells17,28.  We observe increases in PAI-1 expression at 
both the mRNA and protein levels (Figure 5.1C). 
   
 
  108 
 
 
Figure 5.1.  Endothelial cell senescence is induced through serial passaging.  (A) 
Senescence-associated beta galactosidase stain comparing passages 3, 6, and 9.  Expression 
levels of p16INK4a (B) and PAI-1 (C) in serial passaged HUVEC at the mRNA and protein 
level.  mRNA expression analysis was performed by real time PCR and is relative to 
GAPDH.  Protein levels were measured by immunoblot (IB) and expression levels were 
quantied relative to GAPDH using ImageJ.  * denotes p<0.05 and ** denotes p<0.01 vs 
passage 3.   
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Serial passaging is associated with faster rates of clot formation and increased thrombin 
generation. 
In order to determine procoagulant potential of senescent endothelial cells, HUVEC were 
stimulated with TNF-α and examined by plasma clotting assays.  We observed that the rate 
of fibrin assembly increases with passage number (Figure 5.2A), indicative of faster clot 
formation.  We also observed increases in the peak amount of thrombin generation by CAT 
(Figure 5.2B), suggesting that senescent HUVEC support greater thrombin generation on the 
cell surface. 
 
Effect of serial passaging on the fibrin network density of clots formed on the cell 
surface. 
Thrombin concentration is known to determine clot fibrin network density29,30.  Clots 
with denser, more tightly woven fibrin networks are more stable and less prone to lysis than 
those clots with loosely woven fibrin networks.  We used confocal microscopy to measure 
this parameter in senescent HUVEC.  We observed that fibrin network density increases with 
serial passaging (Figure 5.3).  This suggests that as HUVEC undergo senescence, they 
support the formation of more dense, stable clots on the cell surface. 
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Figure 5.2.  Senescent endothelial cells display faster clot formation and increased 
thrombin generation.  (A) Rate of clot formation over cells as measured by plasma clotting 
assay.  (B) Peak thrombin generation in plasma over cells measured by calibrated automated 
thrombography (CAT).  * denotes p<0.05 and ** denotes p<0.01 vs passage 3. 
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Figure 5.3.  Clots formed over senescent endothelial cells show increased fibrin network 
density.  (A) Plasma clots formed over cells using FITC-labeled fibrinogen were analyzed by 
confocal microscopy.  Images were quantified using ImageJ.  * denotes p<0.01 vs passage 3.  
Data are expressed as percent density compared to passage 3.  (B) Representative images 
from passage 3 (left), 6 (middle), and 9 (right) are shown.  N = 3 separate experiments with 
samples in triplicate. 
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Increases in the rate of clot formation and fibrin network density are independent of 
increased tissue factor activity. 
Endothelial-derived tissue factor (TF) is a potent modulator of clot formation in vitro.  
We analyzed TF activity on serial passaged HUVEC by measuring generation of FXa.  We 
observed no difference in FXa generation (Figure 5.4), suggesting the changes in clotting 
parameters were not due to elevated TF activity on the endothelial cell surface. 
 
Serial passaged HUVEC generate less activated protein C and express less 
thrombomodulin. 
The protein C system is an important negative regulatory pathway that limits the 
propagation of thrombin when activated protein C (APC) is generated on the endothelial cell 
surface6,31.  The cleavage of protein C to APC was measured in senescent HUVEC by 
chromogenic assay.  We observed significant reductions in APC generation as HUVEC were 
serial passaged (Figure 5.5A).  This could be due to either reduced expression of 
thrombomodulin (TM) or endothelial protein C receptor (EPCR).  Immunoblot analysis 
showed reduced expression of TM in late passage HUVEC with no change in EPCR 
expression (Figure 5.5B).  
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Figure 5.4.  Endothelial cell senescence is not associated with increased tissue factor 
activity.  Tissue factor (TF) activity assay performed using a chromogenic substrate for FXa 
after incubating cells with FVIIa and FX.  Data are expressed as percent FXa generation 
compared to passage 3. 
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Figure 5.5.  Senescent endothelial cells show reduced protein C activation.  (A) The 
cellular potential to activate protein C was assessed using a chromogenic substrate activated 
protein C after incubating cells with thrombin and protein C and quenching the reaction with 
antithrombin and heparin.  * denotes p<0.01 vs passage 3.  Data are expressed as percent 
protein C activation compared to passage 3.  (B) Western blot analysis quantifed in ImageJ 
showing protein throbomodulin (left) and endothelial protein C receptor (EPCR) (right) 
levels relative to GAPDH. 
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Aged mice display decreased endothelial thrombomodulin expression. 
Our results showing reduced TM expression in serial passaged HUVEC was confirmed in 
vivo using lungs from aged mice.  Lungs were subjected to IHC analysis and representative 
images are shown from 2 month (top) and 24 month (bottom) old mice (Figure 5.6).  Aged 
mice display reduced TM staining, consistent with our in vitro findings and in vivo findings 
from other groups19. 
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Figure 5.6.  Decreased thrombomodulin expression is observed in aged mice.  Mouse 
lungs were analyzed by immunohistochemistry to determine thrombomodulin protein levels 
between 2month (top) and 24 month (bottom) old mice.  Representative images are shown.  
Arrows demonstrate vascular endothelium. 
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5.4 Discussion 
The vascular endothelium is an important regulator of blood homeostasis.  Maintaining 
vascular endothelial cell integrity and function is critically important for conserving the 
anticoagulant nature of the vessel wall and preventing the inappropriate formation of 
thrombi.  Endothelial cell dysfunction is a major risk factor for venous thrombosis and also a 
known consequence of aging in humans15,32,33.  Cellular senescence can promote vascular 
dysfunction with aging by causing phenotypic changes in endothelial cells that may 
predispose the elderly to venous thrombosis25,26.  There is little current literature 
demonstrating these phenotypic changes in senescent endothelial cells in vitro and no reports 
on how these changes alter clotting parameters on the cell surface.  Here we observe that 
serial passaging HUVEC induces cellular senescence in vitro and is associated with several 
phenotypic changes consistent with previous reports, in addition to novel changes and how 
they affect plasma clotting. 
In order to induce cellular senescence in vitro, HUVEC were serial passaged and cells at 
early (3), middle (6) and late (9) passage were compared for markers of senescence.  We 
observed increased expression of SA β-galactosidase, p16INK4a, PAI-1 which are known 
markers of endothelial cell senescence (Figure 5.1).  These data suggest that cellular 
senescence can be induced in vitro in HUVEC by serial passaging. 
Vascular endothelial cells are important mediators of coagulation by providing both pro 
and anticoagulant factors.  Differences in cellular contributions to clotting can be measured 
by standardizing plasma factor contributions by using normal, pooled, platelet-free plasma.  
Thus, any observed differences in clotting parameters are not due to varying plasma or 
platelet factors, but are due to changes in procoagulant potential of the cellular conditions 
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tested34.  Once a model of endothelial cell senescence had been established, the effect of 
senescence on procoagulant potential was analyzed in plasma-based assays.  We observed 
increases in the rate of fibrin assembly (Figure 5.2A) and increases in thrombin generation 
(Figure 5.2B) on the cell surface of senescent HUVEC.  This suggests that senescent 
endothelial cells generate clots more rapidly and support greater thrombin generation, and are 
therefore prothrombotic. 
Fibrin clot structure is thought to be important in determining pathophysiologic features 
of bleeding and thrombosis29,30.  The density and stability of a fibrin clot is determined by the 
concentration of thrombin in the reaction.  Clots formed in the presence of low levels of 
thrombin have thick, loosely woven fibrin fibers that are easily dissolved by lytic proteins.  
These clots are considered to be less stable and could potentiate bleeding.  On the contrary, 
clots formed in the presence of high concentrations of thrombin are composed of thin, tightly 
woven fibrin fibers.  These clots are more stable, however less susceptible to fibrinoysis and 
may predispose individuals to thrombosis29.  Thus, the ability of senescent endothelial cells 
to support greater thrombin generation could have a significant effect on clot stability.  Fibrin 
clot structure was measured by confocal microscopy in clots formed on the cell surface of 
serial passaged HUVEC in the presence of fluorescently tagged fibrinogen.  We observed 
increased density of fibrin networks in clots formed over late passage HUVEC compared to 
those formed over early passage HUVEC (Figure 5.3).  These data suggest that clots formed 
over senescent HUVEC are more stable, would be less prone to lysis and could contribute to 
pathologic thrombus formation in an in vivo setting. 
Tissue factor (TF) is a potent initiator of coagulation.  The amount of TF produced by a 
cell directly affects clot formation and thrombin generation and is a major determinant of 
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cellular procoagulant activity27.  In order to determine if increased TF activity in senescent 
HUVEC was the cause of increases in thrombin generation and rates of clot formation and 
stability, TF activity was measured by extrapolating the rate of FXa generation in a 
chromogenic assay.  No difference in TF activity was detected between serial passaged 
HUVEC (Figure 5.4), suggesting that the prothrombotic phenotype observed in senescent 
cells was independent of TF. 
Changes in anticoagulant proteins could also contribute to a prothrombotic phenotype 
secondary to senescence.  The protein C pathway inhibits the propagation of thrombin.  The 
key regulatory protease of the protein C pathway is activated protein C (APC), which is 
generated when thrombomodulin (TM) on the endothelial cell surface binds to thrombin and 
cleaves zymogen protein C.  Protein C is brought to the thrombin/TM complex following 
binding to endothelial protein C receptor (EPCR).  APC, with its cofactor protein S, 
downregulates thrombin generation by inactivating factors Va and VIIIa6,31.  In vivo murine 
models demonstrated that loss of TM on the endothelial surface leads to a reduced capacity 
to generate APC and results in spontaneous thrombosis35.  Importantly, a recent publication 
has shown that high mortality associated with induction of endotoxemia in aged mice was 
correlated with decreased expression of TM and reduced APC generation19.  To determine if 
the increased thrombin generation and enhanced fibrin clotting parameters in senescent 
HUVEC were the result of dysregulation of the protein C pathway, the ability to support 
APC generation on the cell surface of serial passaged HUVEC was measured by 
chromogenic assay.  We observed a significant reduction in APC generation as endothelial 
cells were passaged (Figure 5.5A).  This reduction in APC generation can be due to either 
decreases in endothelial production of TM or EPCR.  Expression levels of both proteins was 
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measured by immuoblot analysis.  We found that serial passaging was associated with 
decreased production of TM, with no observed effect in EPCR levels (Figure 5.5B).  We 
confirmed this finding and the reports from other groups of reduced TM in aging endothelial 
cells, by performing IHC analysis on lungs from mice aged 2 and 24 months.  Here we see a 
reduction in endothelial TM staining in the lung (Figure 5.6), suggesting that decreased TM 
expression in endothelial cells leads to reduced APC generation both in vitro and in vivo. 
In conclusion, these findings suggest that endothelial cell senescence could be an 
important mediator of vascular dysfunction in the elderly.  Although it is not entirely clear 
whether these endothelial changes are p16INK4a-dependent or are an artifact of cell culture, 
corroborative data in vivo suggests that these results are relevant and provide a novel report 
of changes in the aging vasculature could predispose elderly individuals to venous 
thrombosis.  
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Chapter 6. 
Age-related Changes in Thrombus Formation, Thrombus Resolution, and Blood 
Coagulability in Mice 
 
6.1  Introduction 
Venous thromboembolism (VTE) is the term encompassing both deep vein thrombosis 
(DVT) and pulmonary embolism (PE), a very serious and lethal complication of DVT.  The 
incidence of VTE is approximately 1 in 1000 individuals in the general population1,2 and it is 
estimated that over 250,000 VTE patients are hospitalized each year, contributing to the 
significant healthcare burden associated with cardiovascular disease3.  The strongest and yet 
most unchangeable risk factor for VTE is age4.  After the age of 55, the risk of suffering from 
VTE goes up substantially and the incidence of those 75 years and older increases to 1 in 100 
individuals; a ten-fold increase from the overall, non-stratified population incidence2,5. 
The relationship between aging and VTE is not well understood.  The natural history of 
venous thrombosis and thrombus resolution includes a role for both plasma and endothelial 
derived proteins, platelet adhesion/activation/aggregation, static flow conditions, and 
leukocyte migration.  Therefore, elevated plasma factor levels, decreased natural 
anticoagulant production, endothelial dysfunction, thickening of venous valves, blood cell 
composition and inflammation are all potential contributors to the risk of thrombosis with 
age. 
  125 
Several groups have described phenotypic changes occurring in genetic mouse models of 
premature aging.  However, there is limited literature on mouse models of true aging and the 
effects on venous thrombosis.  Naturally-aged mice are more susceptible to endotoxemia, 
with augmented upregulation of PAI-1 transcription and renal fibrin deposition following 
treatment with lipopolysaccharide6.  Endotoxemia also caused greater loss of activated 
protein C (APC) generation due to reduced thrombomodulin expression in lungs of aged 
mice7, suggesting dysregulation of this important thrombin-regulating pathway may also 
contribute to thrombotic risk with age.  Elevated levels of circulating tissue necrosis factor 
alpha (TNFα) observed in aged mice following restraint stress led to significant induction of 
tissue factor (TF) expression, a potent initiator of coagulation8.  Additionally, stasis is a well-
known risk factor for venous thrombosis and stasis promoted by immobility is common in 
the elderly.  Aging in mice was found to enhance stasis-induced thrombosis with marked 
increases in several endothelial and circulating factors including endothelial P-selectin and 
PAI-1 expression, leukocyte microparticle (MP) formation and MP-TF activity9.  
Conversely, Stampfli et al found no increase in arterial thrombosis in old compared to young 
mice.  However, they reported impaired arterial endothelium vaso-relaxation but with no 
changes in TF, TM, PAI-1 and inflammatory mediator expression in aged mice10.  Taken 
together, these studies collectively suggest that the pathophysiology of thrombosis in the 
elderly is multifactorial and that aging may disproportionately affect venous over arterial 
thrombosis in mouse models. 
Coagulation and aging are two complex biological processes and the relationship 
between them is not well understood.  In this study, we characterize several hemostatic 
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parameters in aged, wild-type C57BL/6 mice and the effects on venous thrombosis to 
determine mechanistic insights behind the increased risk of VTE in the elderly.  
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6.2  Materials and Methods 
Mice 
All animal procedures were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee, UNC-Chapel Hill.  Mice aged 6 and 12 
months were purchased from the Aged Rodent Colony through the National Institute on 
Aging.  Young, 2 month old control mice were purchased through Charles River 
Laboratories International, Inc.  All mice included in this study were male, C57BL/6 (wild-
type).  
 
Complete Blood Count 
Whole blood collected from inferior vena cava venipuncture into citrated (1:9) tubes was 
analyzed for complete blood counts (CBC) in house using a Hemavet HV950FS 
Multispecies Hematology Instrument (Drew Scientific, Inc.). 
 
FeCl3 Vascular Injury 
The ferric chloride (FeCl3) injury model to the saphenous vein was performed as previously 
described11.  Briefly, the saphenous vein of anesthetized mice was exposed and dissected 
away from the saphenous artery.  A 0.5 x 2 mm piece of filter paper was soaked in 7.5% 
FeCl3 (Sigma Aldrich – F7134), and laid over the saphenous vein for 2 minutes.  The filter 
paper was then removed and the tissue was washed 3 times with warm saline.  Blood flow 
was monitored using a 20-MHz Doppler flow probe (Indus Instruments – Webster, TX).  
Occlusion was defined as the absence of blood flow for one minute. 
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Thrombin Generation 
  Thrombin generation was measured by calibrated automated thrombography (CAT) using 
Z-Gly-Gly-Arg-AMC fluorogenic substrate for thrombin (Diagnostica Stago, Parsippany, 
NJ) on a Fluoroskan Ascent fluorometer (ThermoLabsystem, Helsinki, Finland).  Mouse 
plasma was analyzed as previously described12.  Briefly, mouse plasma samples were diluted 
1:4 in phosphate buffered saline and 80 µL of plasma was added to 20 µL low tissue factor (1 
pM) reagent to initiate thrombin generation upon administration of substrate containing 
calcium.  Variations in plasma color were accounted for using a α2-macroglobulin/thrombin 
calibrator reagent (Diagnostica Stago, Parsippany, NJ).  Parameters were calculated by 
Thrombinoscope software version 3.0.0.29 (Thrombinoscope BV, Maastricht, Netherlands). 
 
TAT ELISA 
TAT complexes were detected in mouse plasma using an Enzygnost TAT complex ELISA 
(Siemens – New York, NY, USA).  Plasma samples were diluted 1:10 in Enzygnost ELISA 
sample buffer.  ELISA was performed according to the company protocols and standard 
curves were generated using proteins supplied by the company. 
 
IVC Ligation 
Stasis-induced venous thrombosis by inferior vena cava (IVC) ligation was performed in 
anesthetized mice by exposing the IVC by laparotomy and dissecting it away from the aorta.  
A single ligature was placed around the IVC just below the renal vein branching using a 8-0 
prolene suture.  To achieve complete stasis, associated side and back branches were ligated 
or cauterized, respectively.  The laparotomy was closed by first suturing the peritoneum with 
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an absorbable, 5-0 vicryl suture followed by suturing the skin with an 8-0 prolene suture.  
Mice were euthanized 1, 3, 7, and 14 days post surgery for collection of thrombi. Thrombi 
were normalized to length of the effected vessel and data are expressed as weight/length. 
 
Histology and Immunohistochemistry 
Tissues were extracted and fixed overnight in 4% paraformadehyde.  Tissue embedding and 
cutting was performed in the UNC Linberger Comprehensive Cancer Center Animal 
Histopathology Core Facility.  Five micron sections were cut from paraffin blocks and 
deparaffinized and rehydrated for histologic staining and for immunohistochemistry (IHC).  
Tissues were hematoxylin and eosin (H&E) stained to visualize thrombi.  Trichrome staining 
for collagen was performed using a kit purchased from Sigma (HT15-1KT) according to the 
supplier instructions.  For IHC, antigen retrieval was performed in Target Retrieval Solution 
(Dako – Capinteria, CA, S1699) in a 95°C water bath for 10 minutes. Slides were blocked for 
1 hour in 5% serum derived from the species in which the secondary antibody was made and 
subsequently stained with antibodies against fibrin (Gift of Dr. Marshall Runge and Dr. Alisa 
Wolberg, 59D8, 1:1000), PAI-1 (Molecular Innovations ASMPAI-GF-HT, 1:250 dilution), 
F4/80 (Serotec MCA497GA, 1:250), Ly6G (eBioscience 14-5931-82, 1:500) or 
Thrombomodulin (R&D Systems MAB3894, 1:500) for 1 hour at room temperature in a 
humidity-controlled chamber.  Biotinylated secondary antibodies were obtained from Vector 
Laboratories.  Tissue slides were developed using the avidin-biotin complex (ABC) method 
using reagents and protocols obtained from Dako.  Negative control tissue sections were 
stained simultaneously in the absence of primary antibody.  To analyze stained tissues, 
images were collected at 10x magnification with an Olympus BX51W1 light microscope 
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(three images per tissue section) and the average number of positive pixels per image was 
quantified using Adobe Photoshop™ (version 10.0.1). 
 
Statistics 
All statistics were performed using GraphPad Prism.  One-way ANOVA or Students T-test 
were performed where indicated.  Vertical bars represent either standard error of the mean 
(SEM), 95% confidence interval (CI), or range where indicated.  Values of p<0.05 were 
considered statistically significant. 
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6.3  Results 
Aging in mice accelerates occlusive thrombus formation in a FeCl3 injury model. 
The prothrombotic potential in aged mice was examined in an acute FeCl3 injury model 
to the saphenous vein.  Vascular occlusion times were measured in mice aged 2, 6, and 12 
months after treatment with 7.5% FeCl3 to the saphenous vein (n=4-7 mice per group).  
While a trend was apparent across all ages, a significantly shorter time to occlusion was 
observed in 12 month old mice (6.9 ± 1.2 min) compared to 2 month old mice (9.1 ± 1.5 min) 
(Figure 6.1).  These results in mice are consistent with the notion that aging in humans is 
associated with an increased risk of venous thrombosis following vessel wall injury13,14.  
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Figure 6.1.  Aged mice display a decreased time to vascular occlusion in a FeCl3 injury 
model.  Vascular occlusion times were compared between mice aged 2, 6, and 12 months 
after 7.5% FeCl3 injury to the saphenous vein.  Occlusion was defined as the absence of 
blood flow for 1 minute as measured by doppler.  Data is represented as time to form an 
occlusive thrombus in minutes.  * denotes p<0.05 compared to 2 month old mice by student 
t-test. 
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Effect of aging in mice on Complete Blood Count (CBC). 
In order to determine if differences in murine blood cell composition with age could 
contribute to differences in FeCl3-mediated occlusion times, complete blood counts (CBC) 
were measured in mice aged 2, 6, and 12 months (n=5 mice per group).  In general, levels of 
circulating platelets and leukocytes were increased with age in mice.  More specifically, an 
age-dependent increase in platelet counts was observed between 2, 6, and 12 month old mice 
(596.2 ± 32.3, 719.2 ± 47.7, and 812.8 ± 64.8 x103/µL, respectively).  Lymphocyte counts 
ranged from 5.6 ± 1.1 x103/µL at 2 months to 5.5 ± 0.9 x103/µL at 6 months and 7.4 ± 0.9 
x103/µL at 12 months.  Neutrophil counts were increased in 12 month old mice (1.0 ± 0.3 
x103/µL) compared to 2 month old mice (0.5 ± 0.1 x103/µL).  Lastly, monocyte counts were 
only slightly elevated at 12 months of age (0.2 ± 0.04 x103/µL) compared to 2 months (0.3 ± 
0.2 x103/µL).  These results are consistent with previous findings showing similar relative 
changes in blood cell counts as mice age15.  
Figure 6.2 shows our aging mouse results compared with findings in aging humans.  
Interestingly, aging in humans is associated with a decrease in platelet count16.  Additionally, 
aging humans also show decreases in lymphocytes17, neutrophils and monocytes18 with age.  
Collectively, these results show that CBC values in mice (C57BL/6) and humans follow very 
different trends during aging. 
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Figure 6.2.  Aged mice have increased circulating platelet and leukocyte counts.  
Complete blood counts with differentials were performed on mice aged 2, 6, and 12 months.  
These data are plotted against historical data on human platelet and leukocytes counts for 
comparison16-18.  Vertical bars on mouse data points were plotted to represent those published 
for human data: Platelet data – vertical bars represent 95% CI, # denotes p<0.01 vs 2 month, 
* denotes p<0.05 vs 6 month, † denotes p<0.001 vs 2 month.  Lymphocyte data – vertical 
bars represent SEM, * denotes p<0.05 versus both 2 and 6 month.  Neutrophil data – vertical 
bars represent SEM, * denotes p<0.05 vs 2 month.  Monocyte data – vertical bars represent 
SEM. 
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Aging in mice is not associated with increased plasma hypercoagulability. 
Circulating thrombin/antithrombin (TAT) complex formation and thrombin generation 
were used as markers of hypercoagulability in plasma from aged mice (n=4-5 per group).  No 
difference in circulating TAT complex levels was observed in the plasma from mice aged 2, 
6, and 12 months (10.3 ± 3.7, 7.3 ± 0.8, and 8.3 ± 2.8 ng/mL, respectively) (Figure 6.3A).  
Interestingly, this is contrary to historical findings in aged humans19 (Figure 6.3A). 
Next, plasma from untreated mice aged 2, 6, and 12 months was analyzed by calibrated 
automated thrombography (CAT) (n=5 per group).  CAT parameters demonstrated reduced 
thrombin generation in plasma with age as evidenced by prolonged lagtime between 2, 6, and 
12 month old mice (4.0 ± 0.3, 4.3 ± 0.2 and 5.3 ± 0.9 min, respectively), time to peak (TTP) 
between 2 and 12 month old mice (9.6 ± 0.6 and 17.83 ± 5.4 min, respectively) and 
diminished peak thrombin levels between 2 and 12 month old mice (26.2 ± 2.8 and 21.2 ± 
2.5, respectively).  No significant difference between young (737.4 ± 124.9 nM) and aged 
(672.5 ± 256.6 nM) mice was detected in endogenous thrombin potential (ETP).  Figure 6.3B 
shows data generated in aged mice compared with representative data on human thrombin 
generation by CAT20.  As humans age, they display shortened lagtime and TTP and elevated 
peak and ETP, which implies plasma hypercoagulability as humans age.  In contrast, our 
results in mice show reduced thrombin generation with age, suggesting plasma 
hypocoagulability. 
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Figure 6.3.  Aged mice generate less thrombin but have no difference in circulating 
TAT levels.  (A) Levels of circulating TAT complex were measured by ELISA in plasma 
from mice aged 2, 6, and 12 months.  These data are plotted against historical data on human 
TAT levels with age19.  Vertical bars represent 95% CI.  (B) Mouse plasma samples were 
diluted 1:4 and analyzed by CAT to measure thrombin generation parameters.  These data are 
plotted against historical data on human thrombin generation parameters measure by CAT20.  
Vertical bars represent SEM.   * denotes p<0.05 vs 2 month with the exception of data for 
lagtime for which * denotes p<0.05 vs 6 month and # denotes p<.01 vs 2 month.    
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Effect of aging in mice on stasis-induced thrombus formation and resolution. 
 To further explore the age-related changes in thrombus formation, especially given 
the differences seen between the FeCl3 results with the accompanying CBC and plasma 
coagulability values, we performed stasis-induced thrombosis by inferior vena cava (IVC) 
ligation.  Mice aged 2 and 12 months (n=4-8 per group) were analyzed in a model of IVC 
stasis-induced thrombosis to compare thrombus formation and resolution over time (up to 14 
days).  There was no significant differences between young and old mice either in thrombus 
formation or in resolution, as measured by thrombus size over time (Figure 6.4A). 
 Further histological analysis was performed on thrombi to determine if there were 
qualitative or quantitative differences between the young and old mice that could not be 
detected by gross measurements.  Fixed and paraffin embedded thrombi with associated 
vessel wall were analyzed histologically to determine differences in thrombus composition 
between young (2 months) versus old (12 months) mice.  Hematoxylin and Eosin (H&E) 
staining did not show relevant differences in morphology, with the exception of increased 
proteinaceous content in the thrombi from aged mice at the 1 day time point.  Representative 
H&E images are shown in Figure 6.4B.   
 Immunostaining was performed on thrombi to determine any quantifiable differences 
in thrombus composition by examining relevant vessel wall and soluble proteins, as well as 
relevant inflammatory leukocytes.  As seen in Figure 6.4C, heavy fibrin content is present 
early in thrombus formation with fibrin staining decreasing over time as inflammation and 
resolution occurs.  We observed endothelial expression of thrombomodulin (TM) at early 
time points, followed by diminished expression over time.  Trending decreases in TM 
staining at the 1-day time point was observed in aged mice, similar to that recently reported7.  
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Neutrophil infiltration, evidenced by staining for the neutrophil marker Ly6G, occurred by 3 
days post ligation, peaked at 7 days and decreased as macrophage infiltrates were 
subsequently recruited into the thrombus (F4/80 surface marker) in both aged and young.  
PAI-1 staining was seen only on the endothelium at early time points; however, increases in 
soluble PAI-1 staining was found within the thrombus at later days in both mice.  Significant 
increases in PAI-1 expression were found in old mice, consistent with previous reports6.  
Collagen deposition occurred at later stages, with no differences between young and old mice 
observed.  With the exception of changes to PAI-1 levels, these results suggest that there is 
no apparent differences in thrombus mass or composition between 2 and 12 month-old mice 
using a stasis-induced IVC thrombosis model.  
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Figure 6.4.  No difference in stasis-induced thrombus size or histologic properties are 
observed in young compared to old mice.  (A) Mice aged 2 and 12 months were subjected 
to IVC ligation to promote stasis-induced thrombosis.  Thrombus mass was measured over 
time and represented as thrombus weight over length.  (B) Thrombi were H&E stained and 
representative images selected for comparison.  (C) Thrombi were immunostained for 
proteins and cell markers involved in venous thrombus formation and resolution.  
Quantification was performed using Photoshop to count the number of positively stained 
pixels.  Data are represented as positive pixels throughout thrombus age in days. 
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6.4 Discussion 
The increased risk of VTE with age is poorly understood.  Several groups have reported 
phenotypic changes or altered responses to injury in mouse models of aging that have offered 
mechanistic insight behind the relationship of age to thrombosis6-10,21.  The goal of this study 
was to further define these age-dependent changes that may contribute to VTE using well-
defined thrombosis models in aged mice. 
Initially, we confirm the findings of other groups that aged mice display a prothrombotic 
phenotype9.  We performed an acute chemical injury to the saphenous vein using FeCl3 to 
initiate thrombosis and monitored the time to vascular occlusion by Doppler flow meter.  
Aged mice had a significantly shorter time to occlusion compared to young controls 
suggesting that aging is associated with a prothrombotic phenotype in mice in this model. 
According to Virchow’s Triad, venous thrombosis is caused by alterations to one or more 
of the three critical components in the venous circulation:  blood cell and plasma 
composition, the vessel wall, and shear stress/flow22-24.  In that light, we explored changes to 
these components in aged mice that may contribute to the observed prothrombotic 
phenotype.  We analyzed whole blood by CBC to determine age-dependent differences that 
may be driving thrombus formation.  We found that aged mice had significant increases in 
platelet counts and several leukocyte subsets that could contribute to increased thrombosis.  
Importantly, this is not a phenomenon seen in aging humans, who typically display age-
dependent decreases in platelet and leukocyte counts16-18.   
Plasma hypercoagulability is another well-documented phenomenon in human VTE 
patients and elderly individuals and is thought to contribute to the increased risk of 
thrombosis.  We also analyzed aged mouse plasma to determine if plasma hypercoagulability 
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was contributing to the prothrombotic phenotype.  Interestingly, we found reduced overall 
thrombin generation and no difference in circulating TAT levels in aged mice.  These data 
suggest that mice do not display age-related plasma hypercoagulability, which is in contrast 
to aging in humans19,20. 
In order to determine if the prothrombotic phenotype observed in aged mice upon acute 
chemical injury was apparent in another mouse model of thrombosis, we performed IVC 
ligation on 2 and 12 month old mice to promote stasis-induced thrombosis.  This model is 
widely used to study venous thrombosis in a more physiologically relevant setting to 
augment studies using chemical, photoreactive or laser injuries25-27.  We observed no 
difference in stasis-induced thrombosis and resolution over time between young and old 
mice, suggesting that aged mice are not prothrombotic in this model.  Our data differ from 
those reported in McDonald et al where a significant difference in thrombus size between 
young and old mice was observed following IVC ligation for 2 days9.  Indeed, we did see a 
slight increase in thrombus size at this early time point, however expanding this study out to 
longer time points revealed no significant difference. 
As previously mentioned, Stampfli et al reported endothelial dysfunction with aging in 
mice in the absence of any prothrombotic phenotye in the arterial circulation.  There was also 
no observed difference in several key hemostasis factors (including TF, TFPI, TM, and PAI-
1), TAT complex levels, PT and aPTT, and platelet function.  These data suggested that in 
the absence of other physiologic modifiers  (e.g. atherosclerosis, hypertension or diabetes) 
during normal mouse aging on a standard chow diet, aging alone is not sufficient to promote 
arterial thrombosis10. 
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We observe that the age-related susceptibility to venous thrombosis is dependent upon 
the thrombosis model used.  Similar to data from Stampfli et al and in agreement with the 
notion that aging is associated with oxidative stress28-31, we find that directly damaging the 
vessel wall with FeCl3 and inducing oxidative damage results in an accelerated time to 
occlusion in aged mice.  The observed prothrombotic phenotype in this model could be due 
to endothelial dysfunction in aged mice increasing the susceptibility to chemical damage, 
increasing the vessel wall permeability allowing FeCl3 to come in contact with flowing 
blood, or enhanced endothelial denudation enabling exposure of subendothelial tissue factor 
and other matrix proteins.  Increases in platelet and leukocyte numbers could also play a role 
in promoting vascular occlusion in this model through enhanced recruitment and binding of 
these cell types to the damaged vessel.  Conversely, we did not see an effect of age in a 
model of stasis-induced thrombosis.  While we did observe increased PAI-1 levels, trending 
increases in F4/80 positive leukocytes and trending decreases in TM in aged mice, this did 
not have an effect on thrombus weight.  Therefore, while aged mice are prothrombotic 
following oxidative vascular injury, they are not increasingly susceptible to stasis-induced 
thrombosis compared to young mice. 
In conclusion, our data suggest that increased venous thrombosis in aged mice is 
dependent on the coagulation stimulus.  Importantly, C57BL/6 mice display age-related 
changes in hemostasis parameters that differ from those patterns seen in humans.  Employing 
an alternative mouse strain or inducing other cardiovascular modifiers/risk factors in 
C57BL/6 mice may provide a more relevant model for studying aging and thrombosis. 
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Chapter 7 
Summary and Future Directions 
 
7.1  Summary and future directions 
The complex relationship between aging and the increased risk of VTE is not well 
understood.  Upregulation of the cell cycle inhibitor p16INK4a is an established biomarker of 
aging and inducer of cellular senescence1,2.  Cellular senescence may promote vascular 
dysfunction seen in elderly individuals, predisposing them to venous thrombosis.  To date, 
the contribution of p16INK4a and cellular senescence to the pathophysiology of venous 
thrombosis has not been examined.  This research was focused on determining if p16INK4a is a 
genetic risk factor for the age-related risk of VTE.  We used both in vitro and in vivo 
techniques to determine in which cellular compartment p16INK4a expression was contributing 
to thrombosis. 
In Chapter 3, we analyzed the effect of p16INK4a expression on venous thrombosis in vivo.  
Using a transgenic mouse model of ubiquitous overexpression, we compared venous 
thrombus formation and resolution in several vascular injury models between p16INK4a 
overexpressing and wild-type littermate control mice.  We demonstrated that p16INK4a 
transgenic mice display faster rates of vascular occlusion and delayed thrombus resolution 
upon injury to the saphenous vein.  Additionally, p16INK4a overexpression was associated 
with elevated thrombin generation and increased circulating thrombin-antithrombin (TAT) 
levels in plasma after exposure to low-dose endotoxin.  Furthermore, bone marrow 
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transplantation from a wild-type donor into p16INK4a transgenic mice resulted in correction of 
the observed prothrombotic phenotype, suggesting that p16INK4a expression in hematopoietic 
cells contribute to venous thrombosis3. 
Chapter 4 is a continuation of the studies performed in Chapter 3.  Here, we further 
defined the role of p16INK4a expression in hematopoietic cells to venous thrombus formation.  
Mouse models of stasis-induced thrombosis following inferior vena cava (IVC) ligation 
demonstrate that leukocytes were important contributors to the natural history of venous 
thrombogenesis and thrombus resolution4-6.  We compared thrombi from p16INK4a transgenic 
and wild-type control mice following IVC ligation for 3 days both grossly to determine 
morphologic changes and histologically to examine alterations in protein and cellular 
composition.  Mice overexpressing p16INK4a had larger thrombi compared to wild-type mice 
after IVC ligation, confirming our previous findings in Chapter 3 that p16INK4a expression is 
prothrombotic in a mouse model.  Immunohistochemical analysis demonstrated that p16INK4a 
transgenic mice had significantly elevated expression of the monocyte and macrophage 
marker, F4/80.  In order to determine the contribution of these cell types, monocytes and 
macrophages were depleted by approximately 50% in both transgenic and wild-type mice 
following intravenous injection of clodronate-packaged liposomes.  While both p16INK4a 
overexpressing and control mice demonstrated increased thrombus size following monocyte 
and macrophage reduction, suggesting a role for these leukocytes in clearance of early 
forming thrombi, the difference in thrombus size between the two genotypes was abolished.  
These studies suggest that p16INK4a expression in monocytes and macrophages from the 
hematopoietic compartment contribute to the observed prothrombotic phenotype in p16INK4a 
transgenic mice. 
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In Chapter 5, we analyzed the effect of p16INK4a expression and cellular senescence on 
cell surface clotting parameters in endothelial cells in vitro.  Human umbilical vein 
endothelial cells (HUVEC) were serially passaged to promote upregulation of senescence 
hallmarks in cell culture.  Serial passaging of HUVEC was associated with increases in the 
rate of plasma clot formation, greater thrombin generation and the formation of denser, and 
thus more stable fibrin clots on the cell surface.  This procoagulant phenotype was not due to 
increases in tissue factor (TF) activity.  Furthermore, serially passaging of HUVEC resulted 
in a significant reduction in activated protein C (APC) generation on the cell surface.  We 
found this was due to downregulation of thrombomodulin (TM) expression in late passages.  
These data suggest that senescence in vascular endothelial cells is associated with 
procoagulant phenotypic changes in cell culture. 
Lastly, Chapter 6 examined the contribution of natural aging to thrombus formation, 
thrombus resolution, and blood hypercoagulability in mice.  We observed that mice displayed 
an age-dependent decrease in vascular occlusion time following FeCl3-mediated injury to the 
saphenous vein.  Additionally, aging in mice is associated with increases in platelet, 
lymphocyte, and monocyte counts in whole blood.  Interestingly, aged mice display reduced 
thrombin generation by calibrated automated thrombography (CAT) and no change in TAT 
levels.  Furthermore, stasis-induced thrombosis model showed no difference in thrombus size 
between 1 and 14 days post IVC ligation.  These studies show that susceptibility to venous 
thrombosis in aged mice is dependent on the type and extent of vascular injury.  Also, aging 
in mice results in changes in blood cell composition and plasma coagulability that differ from 
those hemostatic changes observed in human aging7-11, making C57BL/6 mice a challenging 
model to study hemostasis during aging. 
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In conclusion, this dissertation showed in vitro and in vivo that p16INK4a expression and 
cellular senescence associated with aging contributes to venous thrombosis.  Future studies 
should be directed at how p16INK4a expression in monocytes and macrophages contribute to 
thrombogenesis.  Using a monocyte/macrophage-specific p16INK4a knock-out or p16INK4a 
overexpressing mouse model would confirm data from the liposome depletion study and also 
be a more direct way of analyzing the role of p16INK4a expression in monocytes and 
macrophages in driving a prothrombotic phenotype.  In addition, isolation of these cell types 
from whole blood and bone marrow of p16INK4a transgenic mice would allow us to measure 
expression levels of proteins involved in regulating thrombus growth and resolution to 
determine if they differ from wild-type controls.  Also, it remains to be determined whether 
the observed changes in serially passaged HUVEC are p16INK4a -dependent or are an artifact 
of cell culture.  Although many attempts have been made thus far to elucidate these 
mechanisms, we have not yet successfully overexpressed p16INK4a in HUVEC.  Alternatively, 
vascular endothelial cells can be isolated from p16INK4a transgenic and wild-type mice and 
cultured to determine if they differ with regard to plasma clotting parameters and APC 
generation. 
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